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ABSTRACT OF THE DISSERTATION 
The Role of Mesenchymal Stromal Cells and Classical Dendritic Cells in the Maintenance and 
Regulation of the Bone Marrow Niche 
by 
Jingzhu Zhang 
Doctor of Philosophy in Biology & Biomedical Sciences 
Molecular Genetics and Genomics 
Washington University in St. Louis, 2018 
Professor Daniel Link, Chairperson 
 
        The bone marrow niche is an important microenvironment for the regulation of normal and 
malignant hematopoiesis. The first discovered niche component is mesenchymal stromal cells, 
which are the major source for the production and secretion of multiple niche factors. 
Mesenchymal stromal cells are heterogeneous and various transgenes have been used to target 
non-identical but overlapping subpopulations. To further characterize the heterogeneity of 
mesenchymal stromal cells, we tested the targeting specificity of three tissue-specific Cre-
recombinase transgenes. We show that in addition to osteoblasts, Ocn-Cre targets a majority of 
Cxcl12-abundant reticular (CAR) cells and arteriolar pericytes. Surprisingly, Dmp1-Cre also 
targets a subset of CAR cells, in which expression of osteoblast-lineage genes is enriched. 
Moreover, a new tissue-specific Cre-recombinase, Tagln-Cre efficiently targets osteoblasts, a 
majority of CAR cells, and both venous sinusoidal and arteriolar pericytes. These observations 
  
xii 
 
highlight the heterogeneity of mesenchymal stromal cells in the bone marrow and provide tools 
to interrogate this heterogeneity. To further analyze the functional heterogeneity of mesenchymal 
stromal cells, we assessed the function of CXCL12 from different subsets of mesenchymal 
stromal cells on B lymphopoiesis. We show that CXCL12 from Ocn-Cre targeted stromal cells is 
particularly important for the regulation of mature naive B cells and memory B cells, potentially 
through the regulation of their homing and/or retention. This suggests that B cell development 
requires distinct niches at different stages and Ocn-Cre targeted stromal cells may represent a 
specific niche for late-stage B cell development. Besides mesenchymal stromal cells, this thesis 
also assesses the function of a recently identified resident population of murine bone marrow 
classical dendritic cells (BM cDCs). We show that BM cDC ablation results in a secondary, non-
cell autonomous loss of BM macrophages. And more importantly, BM cDCs regulate 
hematopoietic progenitor and stem cell (HSPC) trafficking through a macrophage independent 
pathway, at least in part, through its regulation of sinusoidal CXCR2 signaling and vascular 
permeability. These findings suggest BM cDCs may serve as a novel bone marrow niche 
component regulating HSPCs. Collectively, this thesis improves on the overall understanding of 
the bone marrow niche and provides insights with significant relevance to both basic and clinical 
research.     
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CHAPTER 1: INTRODUCTION TO THE BONE MARROW NICHE, 
MESENCHYMAL STROMAL CELLS AND CLASSICAL DENDRITIC CELLS  
        Hematopoiesis refers to the production of mature blood cells from hematopoietic stem cells 
(HSCs) in the bone marrow, which is tightly regulated by both intra- and extra-cellular signals. 
Hematopoietic differentiation proceeds through a hierarchical order. Uncommitted and quiescent 
HSCs may give rise to proliferative multipotent progenitors, which in turn differentiate into more 
restricted progenitors for the production of different hematopoietic lineages
1,2
. Hematopoietic 
differentiation and proliferation are regulated by the bone marrow microenvironment or niche, 
which includes different types of niche cells, extracellular matrix, and secreted niche factors
3-7
. 
The concept of the niche was first hypothesized by Ray Schofield in 1978, where he proposed 
that a specialized bone marrow niche preserved the ability for stem cells to reconstitute the bone 
marrow
8
. Later, Michael Dexter showed that mesenchymal stromal cell enriched cultures could 
maintain primitive hematopoietic cells ex vivo
9
. Since then, extensive works have been done on 
the bone marrow niche, and recent studies have identified multiple niches to regulate different 
hematopoietic lineages or different stages during hematopoietic development
10-13
.  Abnormal 
hematopoiesis has been associated with multiple diseases, including anemia, blood cancers, 
hemorrhagic disorders, infection-related diseases, and immune system regulation-related 
diseases
14-17
.  Thus, it is important to study the components and functions of the bone marrow 
niche for its regulation of normal and abnormal hematopoiesis.  Better understanding of the bone 
marrow niche will likely improve our knowledge about the initiation and progression of different 
diseases, and may advance the development of more effective treatments. 
        Prior studies on the bone marrow niche have identified multiple major niche components, 
including mesenchymal stem cells, endothelial cells, osteoblast lineage cells, megakaryocytes, 
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macrophages, the sympathetic nervous system,  and the main focus of our lab, mesenchymal 
stromal cells
4-7,10,12,13
.  Although these components have been shown to regulate the development 
and maintenance of hematopoietic progenitor and stem cells (HSPCs), the regulatory 
mechanisms and the molecular pathways involved are not fully understood. Mesenchymal 
stromal cells are mainly found in the perivascular region, thus also referred to as perivascular 
stromal cells, and are the earliest niche component discovered
3,9,10,12,18,19
. These stromal cells are 
the major source for the production and secretion of multiple niche factors, such as stromal 
derived factor-1 (SDF-1 or CXCL12) and stem cell factors (SCF or Kit ligand)
3,10,11
. 
Mesenchymal stromal cells are heterogeneous and various markers have been used to 
characterize non-identical but overlapping subpopulations, including CXCL12 abundant reticular 
(CAR) cells, leptin receptor expressing (LepR
+
) cells, and Nestin-GFP
+
 cells
3,10,20,21
. 
Collectively, these stromal cells are critical for maintaining quiescence and promoting 
proliferation of HSPCs, so it is important to further characterize its subpopulations for their 
potential specific functions and roles in the bone marrow niche.   
        B cells are an important component of the adaptive immune system whose functions include 
antigen presentation and secretion of cytokines and antibodies
22
. In mammals, B cells mature in 
the bone marrow, but also require input from peripheral lymphoid organs
23
. B cells develop 
through a series of different stages which can be identified based on their surface marker 
expression
24
. In the bone marrow, the common lymphoid progenitor (CLP) gives rise to the B 
lymphoid progenitor (BLP)
25
. Dr. Hardy and colleagues have defined the later stages of B cell 
development using Hardy Fractions, referred as Fractions A through F
26,27
.  Pre-pro-B cells are 
defined as Fraction A cells, which are derived from BLPs and retain most gene expressions of 
germline immunoglobulin
43
. Rearrangement of the heavy chain of immunoglobulin (IgH) starts 
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in early pro-B cells, or Fraction B cells, and is completed in late pro-B cells, or Fraction C 
cells
43
. They then express pre-B cell receptor (pre-BCR), which leads to recombination of the 
immunoglobulin light chain, and these cells are defined as Fraction D cells, or pre-B cells
26,27
. 
After light chain rearrangement, these cells are known as Fraction E cells, or immature B cells, 
and they express IgM on the surface
44
. Most immature B cells enter the blood and migrate to the 
spleen for maturation into mature naive B cells, or Fraction F cells, expressing both IgM and 
IgD
26,28-30
. Meanwhile, some immature B cells may mature in the bone marrow
31
. When exposed 
to recognized antigens, mature naive B cells further mature in the periphery to become anti-body 
secreting plasma cells or memory cells
29,30,32
. Memory cells may include memory plasma cells 
and memory B cells, and studies have suggested the bone marrow as a potential 
microenvironment for their maintenance
32-36
. However, it remains unclear how these cells affect 
immune memory and how they are regulated in the bone marrow, which requires further 
research. 
        Dendritic cells (DCs) are found in different tissues with great heterogeneity and functional 
variations
37-39
. Classical or conventional DCs (cDCs) are generally defined as cells with dendritic 
morphology and outstanding capacity for presenting antigens and priming T cells
40,41
. cDCs can 
be further divided into two subsets, type 1 cDCs (cDC1s) and type 2 cDCs (cDC2s). cDC1s are 
mainly responsible for immune responses against viruses, tumors and intracellular pathogens. 
cDC2s are mainly responsible for immune responses against parasites, allergens, extracellular 
bacteria, fungi and some intracellular pathogens
42
.  Besides cDCs, studies have also discovered 
plasmacytoid DCs (pDCs), which are lymphocyte-like cells specialized in the production of type 
I interferons
40,43
. DCs have a myeloid origin and their development consists of a branch of 
hematopoiesis that is different from lymphoid and granulocytic myeloid cell differentiation
44
. A 
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cell population of clonogenic common DC progenitors (CDP) has been discovered in the bone 
marrow (BM), which may differentiate into both cDCs and pDCs
45,46
. Although cDCs mature in 
the peripheral lymphoid organs, clonogenic cDC-restricted progenitors (pre-DCs) have been 
found in the spleen (Sp), BM and other tissues
47,48
, suggesting the capability of cDCs to self-
renew in their resident tissues. Recent studies have shown that BM cDCs mostly reside in the 
BM perivascular region, regulating B cells and neutrophils in the bone marrow
49-51
, although it 
remains unknown whether BM cDCs may regulate HSPCs. BM cDCs and BM macrophages are 
both mononuclear phagocytes with a common myeloid origin, and recent studies have suggested 
BM macrophages may be important for the regulation of HSPCs
7,52,53
. Thus, it would be 
interesting to test whether BM cDCs may function as a novel bone marrow niche component to 
regulate HSPCs. 
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1.1. Components of the Bone Marrow Niche 
1.1.1. Mesenchymal stem cells 
        Mesenchymal stem cells (MSCs) are multipotent stromal cells with the capability to 
differentiate into osteogenic lineage cells, chondrocytes, and adipocytes
4
. To identify MSCs, in 
vitro colony forming assays can be performed to test whether the cells of interest may form all 
three lineages. However, a prior study has identified a population of proliferative osteoblastic 
progenitors, MX-1 positive bone marrow stromal cells, which could differentiate into 
osteolineage cells, chondrocytes, and adipocytes in vitro yet only differentiate into osteoblasts in 
vivo
54
.  Other studies have proposed various markers to identify MSCs in mouse bone marrow, 
including platelet-derived growth factor receptor-alpha and -beta (PDGFRα and PDGFRβ), 
CD51, Sca1 and alpha smooth muscle actin
55-58
.  But until now, no precise and universal 
definition of MSCs exists due to a lack of consensus in defining markers
4
. Recent studies have 
identified Nestin-GFP
+
 cells that are enriched for MSC activity and express high levels of key 
niche factors, such as SCF, CXCL12, PDGFRα, and fibroblast activation protein (FAP)58,59. 
Follow-up studies showed that HSCs localize near Nestin-GFP
+
 cells, and ablation of Nestin-
GFP
+
 cells leads to bone marrow hypocellularity, anemia, and depletion of osteogenic cells
60,61
.  
Our lab and others have discovered that the Prx1-Cre targeted PDGFRα+ Sca1+ (PαS) cells are 
highly enriched for MSCs
3
. To our surprise, these Prx1-Cre targeted PαS cells did not express 
nestin, one possible explanation being that Nestin-GFP transgene does not accurately reflect the 
nestin expression in vivo
3
. Despite the recent research emphasis, the complex population 
heterogeneity remains an obstacle for precisely defining the MSC population and studying them 
in greater detail.  
  
6 
 
1.1.2. Endothelial cells 
       HSPCs preferentially localize to the perivascular regions in the bone marrow
4,5,62
. Prior 
studies have shown that BM endothelial cells (ECs) promote HSPC maintenance, and sinusoidal 
endothelial cells promote long-term HSC reconstituting capability
10,63-66
. In addition, BM ECs 
have been illustrated to release soluble niche factors, referred as angiocrine function
67
.  CXCL12 
and SCF are important niche factors that have been widely investigated in the regulation of 
HSPCs in the bone marrow
10,68-70
. A recent study shows that deletion of Kitl in ECs results in 
decreased HSC numbers and reduces the repopulating capability of HSCs after bone marrow 
transplantation
10
.  In contrast, later studies using similar models to delete CXCL12 in BM ECs 
show minimal decrease in HSPCs and only a modest loss of long-term repopulating capacity of 
HSCs after transplantation
3,11
. Other than secreted niche factors, an EC-specific adhesion 
molecule, E-selectin, is shown to activate HSC proliferation
71
. More recent data suggests that 
activation of endothelial CXCR2 by Gro-β (CXCL2) could induce bone marrow vascular 
permeability and promote HSPC mobilization
72
. Another recent study showed that activation of 
Notch signaling in ECs results in the up-regulation of cellular SCF level and the expansion of 
PDGFRβ+ perivascular mesenchymal cells73. Collectively, these studies provide evidences to 
implicate BM ECs as an important component of the bone marrow niche.  
        BM ECs are heterogeneous, and prior studies have revealed different types of ECs in the 
bone marrow
74
. Sinusoidal capillaries, highly branched small vessels found throughout the 
marrow cavity, are the most abundant blood vessels in the bone marrow
74
. Sinusoidal ECs 
express vascular endothelial cadherin (VEcad) and vascular endothelial growth factor receptor-3 
(VEGFR3), and are laminin
+ or low
 Sca-1
- or low
, while arteriolar ECs are mainly laminin
+
 Sca-1
+
 
VEcad
+
 Vegfr-3
-
 
75,76
. A recent study on the murine postnatal development reveals a novel 
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subtype of blood vessel, type H vessel. These blood vessels express higher levels of endomucin 
(Emcn) and CD31 (Pecam1) compared to sinusoidal vessels, and are found in more proliferative 
regions of the bone marrow
77,78
. Distinct bone marrow niches have been proposed around both 
arteriolar and sinusoidal vessels
12,13,18,79
. The arteriolar niche consists of arteriolar ECs and 
Nestin-GFP
high
 NG2
high
 mesenchymal stromal cells, which are demonstrated to maintain HSC 
quiescence
12
. Arteriolar vessels are less permeable compared to sinusoidal vessels and were 
shown to maintain a low level of reactive oxygen species (ROS) in HSCs, while sinusoidal 
vessels were shown to be important for regulating HSC trafficking and homing
73,79
. In 
comparison, the sinusoidal niche consisting of sinusoidal ECs and LepR
+
 (leptin receptor) 
mesenchymal stromal cells, was illustrated to regulate both quiescent HSCs and more 
proliferative progenitor cells
18
. So far, it remains unclear whether quiescent HSCs are regulated 
by the arteriolar or sinusoidal niche, and it is also possible that both niches may play important 
roles to maintain quiescent HSCs. Although the existence and the exact function of arteriolar and 
sinusoidal niches are still controversial, it is clear that BM ECs and their surrounding 
perivascular niches are critical for the maintenance and development of HSPCs.  
 
1.1.3. Osteoblast lineage cells 
        Osteoblast lineage cells include osteoblasts, osteocytes and osteoblastic progenitors
19,80
. 
Osteoblasts produce bone matrix proteins and have the potential to differentiate into 
osteocytes
81
. Osteocytes are abundant in bones and are important for bone remodeling, 
regulating both osteoblast and osteoclast functions
81,82
. Osteoblastic progenitors or immature 
osteoblasts are bone marrow stromal cells that are likely to differentiate into mature 
  
8 
 
osteoblasts
19
. A recent study showed that transgenic mouse models used previously to study 
osteoblasts or osteocytes in fact target other osteoblast lineage cells or mesenchymal stromal 
cells
19
. Thus, it would be more accurate to discuss the roles and functions of osteoblast lineage 
cells, instead of each individual, in the bone marrow niche.   
        Early studies done by Taichman and colleagues show that osteoblast lineage cells support 
hematopoietic development and HSC maintenance
83,84
. Later experiments show that osteoblast 
lineage cells are necessary for normal hematopoiesis and HSC activities
85,86
. In addition, 
activation of osteoblast lineage cells has been shown to promote the expansion of phenotypic and 
functional HSCs in vivo
21,87-89
. However, another study suggests that the expansion of osteoblasts 
is not sufficient to increase HSC number
90
. Moreover, a later study shows that defects in 
osteoblast function in a murine inflammatory arthritis model are insufficient to impair HSCs
91
. 
While the roles and functions of osteoblast lineage cells on HSPCs remain controversial, recent 
study suggests that they may play more important roles for the regulation of lymphoid 
progenitors, but not HSPCs
11
. The differences among these studies may be caused by the 
heterogeneity of osteoblast lineage cells, and that different subsets may play different roles in 
hematopoiesis
92
. For example, immature osteoblasts marked by high expression of a 
transcription factor, Runx2, may have a greater potential in HSC maintenance and 
enhancement
93
. In contrast, mature osteoblasts and osteocytes that are activated by constitutive 
parathyroid hormone (PTH) signaling have a decreased ability to support HSCs, compared to 
immature osteoblasts
93
. Since the common transgenic models used for studying osteoblast 
lineage cells lack specificity for a certain cell subset
19
, it is necessary to develop better markers 
or models to further dissect this heterogeneous population and to more accurately study its 
function. 
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1.1.4. Megakaryocytes 
        Megakaryocytes (MKs) are hematopoietic lineage cells recognized by their unique 
morphology, especially their large size
94-96
. MKs have been reported to mainly reside in 
proximity to bone marrow sinusoids during hematopoietic homeostasis
97
. Interestingly, after 
irradiation, MKs may relocate from the central marrow space to the endosteal surface
98
. The 
same study shows that MKs promote the expansion of the endosteal niche through its production 
and release of platelet-derived growth factor-BB (PDGF-BB), thus to increase HSC engraftment 
after irradiation
98
. In fact, one major function of MKs is to release different soluble factors in the 
bone marrow
99
. MKs are the main source of thrombopoietin (TPO) which is important for the 
maintenance of quiescent HSCs, and depletion of MKs results in a decrease of intra-BM TPO 
concentration and a decrease in HSC number
100,101
. In addition, MKs are the main source of 
platelet factor 4 (PF4 or CXCL4) in the bone marrow that regulates the cell cycle activity to 
maintain HSC quiescence
102
. In contrast, another group has reported an in vitro study in which 
MKs release insulin-like growth factor-1 and insulin-like growth factor binding protein-3 to 
increase HSC proliferation
103
. To explain the dual functions of MKs for both maintaining HSC 
quiescence and promoting HSC proliferation, Li’s group reported that MKs are the main source 
of transforming growth factor β1 (TGF-β1) and fibroblast growth factor-1 (FGF1). While TGF-
β1 regulates the quiescence of HSCs during homeostatic conditions, MKs switch to promote 
HSC expansion by releasing FGF1 under chemotherapeutic stress
6
. Collectively, prior studies 
have demonstrated that MKs release different soluble niche factors under homeostatic and 
stressful conditions, and they serve as an important bone marrow niche component to regulate 
both quiescence and proliferation of HSCs.  
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1.1.5. Macrophages 
        Macrophages are professional phagocytic cells with great heterogeneity, found in both 
lymphoid and non-lymphoid tissues
38,44,104
.  Most macrophages are capable of engulfing and 
degrading large particles, which allow them to clear foreign and damaged cells
23,88,105
. 
Macrophages are equipped with a broad-range of pattern-recognition receptors (PRRs), which 
are required for engulfing cellular debris and pathogenic particles that leads to the production of 
inflammatory or immunosuppressive cytokines
38,44,104,106
. Macrophages are also highly plastic 
and can shift their physiology rapidly in response to injury or infection
104,107
.  The phenotypes 
and functions of macrophages are largely dependent on the surrounding microenvironment
104
. 
In general, macrophages can be simply classified into two different types: classically activated, 
or M1, macrophages (CAMs), and alternatively activated, or M2, macrophages (AAMs)
108
. 
CAMs are more specialized for antigen presentation, production of nitric oxide (NO), secretion 
of chemokines and cytokines, and promoting T-helper 1 (Th1) lymphocytes expansion
104,107,108
.  
Therefore, CAMs play a critical role in the defense against bacteria, although their defense 
mechanisms may also damage the host
104,108
. In contrast, AAMs are involved in the defense 
against parasites and fungi
109,110
. AAMs express large amounts of cytosolic arginase and 
extracellular matrix related proteins, allowing them to regulate inflammation and promote 
tissue repair, thus they are also referred to as wound-healing macrophages
107,109-111
. 
Additionally, unique subsets of resident macrophages exist in different tissues, such as brain 
microglia, lung alveolar macrophages, and liver Kupffer cells
107,109
. Early studies have 
suggested that most resident macrophages are derived from circulating monocytes with bone 
marrow origin
38,104,105,112,113
. However, recent studies provide clear evidence that resident 
macrophages can proliferate locally in both steady state and stressful conditions, and it remains 
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to be determined whether circulating monocytic precursors or self-renewal is more important 
for resident macrophage homeostasis
105,114,115
. Meanwhile, resident macrophages may also be 
classified into CAMs or AAMs, although their response to a given stimulus can be different 
from regular CAMs or AAMs
116,117
. 
        Bone marrow macrophages were first discovered in 1958 by ultrastructural study, which 
serve as the central component for the erythroblastic island, surrounded by erythroblasts at 
different stages of maturation
118,119,120
. Erythroblastic island macrophages (EIMs) are essential 
for the maturation and survival of erythroblasts
119
. EIMs produce principal growth factors to 
regulate erythropoiesis, such as erythropoietin (EPO)
121-123
, insulin-like growth factor-1 
(IGF1)
124,125
 and bone morphogenetic protein-4 (BMP4)
126
. EIMs also contribute to the 
synthesis of hemoglobin by incorporating iron into ferritin
127
. Moreover, EIMs aid in the 
enucleation process by phagocytosis and degradation of extruded nuclei
128,129
. Another subset 
of BM macrophages resides in the endosteal niche and is referred as osteomacs
119,130
. On 
resting bone surfaces, bone lining cells are interspersed by osteomacs, which are in direct 
contact with the bone surface
119,131
. Osteomacs play an important role in osteoblast formation 
and maturation
103,115
, and can express a wide array of pro-anabolic molecules that are essential 
for parathyroid hormone anabolic actions
132
. Osteomacs may also contribute to injury response 
and tissue regeneration through production of growth factors, inflammatory cytokines and 
chemokines
133,134
.  
        In addition, recent studies reveal that macrophages also localize to the bone marrow 
hematopoietic niche and may support other bone marrow niche components in vitro
52,131,135
.  
Prior studies have used different in vivo macrophage depletion models to assess their function 
and have shown that macrophage depletion results in the suppression of osteoblast lineage 
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cells, reduced expression of important niche factors, HSPC mobilization and marked decrease 
of erythroblasts
7,52,53,131
. In these studies, macrophages regulate HSPCs indirectly through 
regulation of osteoblast lineage cells and Nestin
+
 mesenchymal stem cells
7,135
. Interestingly, a 
more recent study suggests that these macrophages may also regulate HSPCs directly, as 
CD234 on macrophages stabilizes CD82 on long term (LT)-HSCs to promote quiescence
136
. 
Moreover, BM macrophages express high levels of granulocyte colony stimulating factor (G-
CSF) receptor
137,138
, and exposure to the pro-inflammatory factor G-CSF, a commonly used 
HSPC mobilizing reagent, substantially reduces BM macrophages
52,139
. The loss of BM 
macrophages then promotes HSCs to proliferate and mobilize, both directly and 
indirectly
7,135,136,140
. Collectively, evidence suggests BM macrophages serve as an important 
bone marrow niche component, regulating the quiescence, proliferation and mobilization of 
HSPCs under homeostatic and stressful conditions.   
 
1.1.6. The Sympathetic Nervous System 
        The sympathetic nervous system (SNS) is another important bone marrow niche 
component. Prior studies have shown that the SNS regulates HSC mobilization through its 
modulation of granulocyte colony stimulating factor (G-CSF) and/or CXCL12 signaling
141,142
.  
Another study suggests that the SNS stimulates Nestin
+
 mesenchymal cells to send adrenergic 
signals to HSPCs
143
. Meanwhile, non-myelinating Schwann cells are a major source of activated 
transforming growth factor β (TGFβ) in the bone marrow144, and TGFβ  induces HSC quiescence 
ex vivo
145
. There is evidence that ablation of Schwann cells results in decreased HSC dormancy 
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and HSC number
146
. Therefore, the SNS has been proposed as a major component of the bone 
marrow niche.  
        Collectively, all the components discussed above, as well as mesenchymal stromal cells, 
make the bone marrow niche a complicated but critical microenvironment to study. 
Understanding the bone marrow niche will not only enhance our knowledge on hematopoiesis, 
but it will also help us improve treatments for bone marrow related diseases. 
 
1.2. Mesenchymal Stromal Cells 
1.2.1. CAR cells 
        CXCL12-abundant reticular (CAR) cells are identified by the expression of GFP which is 
knocked into the cxcl12 locus
147
. They have a characteristic reticular morphology, with long 
processes extending throughout the bone marrow, and are predominantly perivascular
148
. In 
mouse bone marrow, CAR cells can be defined as Lineage
-
 (CD45, CD31, Ter119 and Gr-1) 
stromal cells expressing high levels of GFP
19
. CAR cells are the main source of bone marrow 
CXCL12, and they also express high levels of SCF
10,149
. A prior study used CXCL12-diphteria 
toxin receptor (DTR) mice to deplete CAR cells, which resulted in HSC reduction in the bone 
marrow
149
. Since CAR cells express both CXCL12 and SCF, CXCL12 from CAR cells may not 
be necessary for HSC maintenance in the bone marrow. To test this possibility, a later study used 
Osterix-Cre (Osx-Cre) and Cxcl12
flox
 models to ablate CXCL12 from CAR cells and found that 
CXCL12 expression from CAR cells, while essential for efficient retention of HSPCs in the bone 
marrow, was not required for HSC maintenance
3
.  
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        CAR cells were originally described as adipo-osteoprogenic mesenchymal progenitors
149
. 
Lineage mapping using Osterix-Cre to target CAR cells shows that both osteoblasts and CAR 
cells are targeted, suggesting the osteoprogenic potential of CAR cells
3
. Meanwhile, Leptin-
receptor-Cre (LepR-Cre) targets both CAR cells and adipocytes, which suggests the adipogenic 
potential of CAR cells
11
. While both models target CAR cells efficiently, they target adipocytes 
and osteoblasts differently, which brings doubts on CAR cell’s adipo-osteoprogenic potentials. 
One possible explanation is that CAR cells may have different adipo-osteoprogenic potentials at 
different time points during development, Osx-Cre and LepR-Cre may be turned on at different 
stages, thus target adipocytes and osteoblasts differently.  
        CAR cells have also been reported to affect B lymphopoiesis. A prior study using the 
diphtheria toxin-ablation model has shown that CAR cells are important for early B cell 
development, as CAR cell ablation results in a loss of CLP, decreased proliferation and increased 
apoptosis of pro-B cells
148
. CXCL12 produced by CAR cells likely plays an important role 
during B cell development, as a recent study has demonstrated the effects of ablating CXCL12 
from different subsets of CAR cells on B cell development
3
. In addition, interleukin 7 (IL-7) has 
been reported to play an essential role in early B lymophopoiesis
150
. Deletion of either IL-7 or 
IL-7 receptor has been shown to cause reductions in pro-B and pre-B lymphocytes with no 
change to pre-pro-B lymphocytes
151-153
. A recent study crossed IL7-Cre transgenic mice with 
Rosa26
EYFP
 mice and illustrated that the IL-7 expressing cells in the bone marrow were 
predominantly bipotent CAR cells
154
.  
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1.2.2. LepR
+
 Cells 
        LepR
+
 cells are stromal cells expressing leptin receptor which were originally identified as 
Lepr-Cre targeted stromal cells by the Morrison group
10
. LepR
+
 cells include more than 90% of 
cells expressing high levels of Scf-GFP or Cxcl12-DsRed in young-adult mouse bone 
marrow
155,156
. LepR
+
 cells are mostly perivascular and especially enriched around sinusoids and 
small-diameter arterioles
156,157
. In normal young-adult mouse bone marrow, LepR
+
 cells and 
CAR cells almost completely overlap with each other
155,156
. Consistent with this observation, a 
later study used Lepr-Cre to conditionally delete Foxc1, a transcription factor that is required 
by CAR cells, which resulted into substantial depletion of HSCs and reduced bone marrow 
cellularity
158
. Therefore, LepR
+
 cells and CAR cells may be considered as the same cell 
population, at least in young-adult mice
156
. Although LepR
+
/CAR cells only represent 
approximately 0.3% of bone marrow cells, their long processes are present throughout the bone 
marrow, providing them the capability to affect most bone marrow cells
156
. LepR
+
/CAR cells 
express both SCF and CXCL12, and are also closely associated with HSCs, thus making them an 
important component of the perivascular bone marrow niche
3,11,76,155,159
.  
 
1.2.3. Nestin-GFP
+
 Cells 
        Nestin-GFP
+
 (Nes-GFP
+
) cells are bone marrow mesenchymal stromal cells expressing GFP 
under the regulatory element of the nestin promoter
21,160
. Histomorphometry analysis of whole 
bone marrow shows two different subsets of Nes-GFP
+
 cells, according to their expression levels 
of GFP and their locations: Nes-GFP
dim
 cells that are perisinusoidal and heavily overlap with 
CAR/LepR
+
 cells; and Nes-GFP
bright
 cells that are periarteriolar and express NG2
156,157
. A prior 
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study done by Frenette’s group used confocal imaging and spatial modeling to reveal that about 
35% of HSCs are closely associated with arterioles
12
. The same study also suggests that these 
arteriolar Nes-GFP
+
 stromal cells and arteriolar niches are indispensable for maintaining HSC 
quiescence
12
. This is in contrast to a later study which shows non-dividing HSCs are mainly 
perisinusoidal
159
.  
        The concept of the periarteriolar niche was initially based on the suggestion that Nes-GFP
+
 
cells, especially the Nes-CreER
 
and NG2-CreER targeted periarteriolar Nes-GFP
bright
 cells, were 
an important source of SCF and CXCL12
12,21
. Since Nes-GFP
+
 cells include two distinct subsets, 
it is not clear whether the SCF and CXCL12 expressed by Nes-GFP
+
 cells reflect the expression 
by perisinusoidal Nes-GFP
dim
 CAR/LepR
+
 cells or the expression by periarteriolar Nes-GFP
bright
 
NG2
+
 cells
156
. Moreover, inconsistent with the original studies
12,21
, other groups revealed that 
conditional deletion of Cxcl12 and Scf in Nes-CreER
 
and NG2-CreER targeted cells showed no 
significant effects on HSC frequency or HSC functions in adult bone marrow
10,11,18,155
.   
Different observations between these groups may be due to the age of mice used in their 
experiments. Studies supporting the arteriolar niche administered tamoxifen to deplete Cxcl12 
from NG2-CreER or Nes-CreER targeted cells within 3 weeks after birth
161,162
, when these Cre 
alleles are more broadly expressed in the bone marrow
163
. Other studies administered tamoxifen 
6 weeks after birth, when NG2-CreER and Nes-CreER are more restricted to periarteriolar 
cells
11,159
. While the function of Nes-GFP
bright
 NG2
+
 stromal cells and the concept of the 
periarteriolar niche still remain debatable, Nestin-GFP
+
 stromal cells do represent an important 
stromal population in the bone marrow niche.  
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1.3. B Lymphopoiesis  
1.3.1. CXCL12 
        CXCL12, also known as stromal-derived factor 1 (SDF-1) was originally discovered as a 
chemokine stimulating pre-B cell development in vitro
164
. CXCL12 is an important chemokine 
for hematopoiesis and B lymphopoiesis
20
, and mice lacking CXCL12 are perinatal lethal with 
significant defects in B cell development
165
. CXCR4 is the primary receptor of CXCL12, and 
mice lacking CXCR4 have a defect in early B cell development, with reductions in pre-pro B 
cells, CLPs and BLPs
166-168
.  CXCL12 interacts with CXCR4 to activate mitogen-activated 
protein kinase (MAPK), PI3 kinase (PI3K), extracellular-signal-regulated kinases (ERK1/2) and 
P38
169
. MAPK activation leads to actin polymerization and the regulation of cytoskeletal change, 
and PI3K activation induces polarization of adhesion molecules; both are responsible for the 
control of chemotaxis
169
. In addition, PI3K and ERK1/2 activate the NFkB pathway for gene 
transcription to promote cell proliferation, while P38 and PI3K down-regulate pro-apoptotic 
factors to inhibit apoptosis and up-regulate anti-apoptotic factors to promote cell survival
20,170
.  
        A prior study used transgenic mice to express an intracellular form of CXCL12 to inhibit 
CXCL12/CXCR4 signaling by sequestering CXCR4 intracellularly and found defects in B cell 
development starting from pro-B cell stage
171
. The same study showed that extracellular 
overexpression of CXCL12 could increase B cell number, further suggesting extracellular 
CXCL12/CXCR4 signaling is important for normal B cell development
171
. In another study, after 
being transplanted into irradiated wild type recipients, fetal liver cells from Cxcl12
-/-
 or wild type 
mice showed indistinguishable capability to reconstitute the hematopoietic system including B 
lymphopoiesis, demonstrating extracellular CXCL12 from the microenvironment, but not from 
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hematopoietic cells, is required for B cell development
172
. In contrast, serial transplantation from 
mice reconstituted with Cxcr4
-/-
 fetal liver cells shows a reduction of B cell progenitors in the 
bone marrow, illustrating the importance of CXCR4 signaling for efficient B cell 
development
172
. In addition to promoting B cell proliferation, CXCL12/CXCR4 signaling may 
also play an important role in regulating B cell retention and trafficking. Transplantation of 
Cxcr4
-/-
 fetal liver cells into wild type recipients results in a decrease of B cells in the bone 
marrow, but an increase of IgM
-
 B cells in the peripheral blood, indicating a retention defect of B 
cell progenitors in the bone marrow
173
. 
        In the bone marrow, mesenchymal stromal cells, especially CAR cells, are the main source 
of CXCL12
3,10
. However, these stromal cells are heterogeneous and may include different 
subsets with more specific functions. The Link lab has used several stromal-specific transgenic 
Cre models to delete Cxcl12 from the bone marrow, including Prx1-Cre, Osx-Cre and Ocn-Cre
3
.  
Prx1-Cre and Osx-Cre models, crossed with Cxcl12
flox/-
 mice, induced significant ablation of 
CXCL12 in the bone marrow, but Ocn-Cre:Cxcl12
flox/-
 mice did not ablate CXCL12 
significantly, compared to Cxcl12
flox/-
 control mice
3
. Interestingly, Prx1-Cre:Cxcl12
flox/-
, but not 
Osx-Cre:Cxcl12
flox/-
 mice,  induced significant reductions in CLPs and BLPs, while both models 
had significant reduction in pre-pro B cells
3
. These observations might be explained by the more 
robust ablation of CXCL12 in Prx1-Cre:Cxcl12
flox/-
 mice, compared to Osx-Cre:Cxcl12
flox/-
 
mice
3
, suggesting B cell progenitors at different stages may be sensitive to different 
concentrations of CXCL12. Another possibility is that the expression of CXCL12 by 
mesenchymal stem cells, targeted by Prx1-Cre, but not Osx-Cre, is required for the development 
and maintenance of CLPs and BLPs. Collectively, further studies are required to understand the 
role of bone marrow stromal CXCL12 in the regulation of B cell development.    
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1.3.2. Memory plasma cells 
        B cells can develop into two major types of memory cells, and they are memory plasma 
cells (PCs) and memory B cells. PCs were initially described in 1948
174
, and were originally 
considered as short-lived cells that secrete either IgM or downstream isotypes 
32
. A later study 
identified long-lived PCs in the bone marrow, which are resting in terms of proliferation and 
migration, but may produce antibodies of humoral memory
32,175
. Thus, these cells may also be 
referred to as memory PCs. Human PCs generally express high levels of CD38 and CD27, and 
low levels of CD20. In mice, the comparable markers are CD138 and B220. To distinguish 
memory PCs from short-lived PCs, genes or markers labeling cell cycle and proliferation may be 
used, such as Ki67. The bone marrow is the major reservoir for memory PCs, and studies have 
suggested that PC progenitors from different lymphoid organs may migrate to the bone marrow 
and differentiate into memory PCs
32
. A prior study has provided some evidence that the 
longevity of memory PCs is an intrinsic feature, but extrinsic signals from the surrounding 
microenvironment are also required for the survival of memory PCs and the prevention from 
apoptosis
32,176
. In the bone marrow, stromal cells have been strongly suggested to constitute an 
important part of the survival niche for memory PCs, either by directly supporting memory PC 
survival, or by recruiting and supporting other important niche components. In both human and 
mouse, PCs express CXCR4, and CXCL12 produced by stromal cells play a critical role for the 
maintenance of memory PCs in the bone marrow
32
. Disruption of CXCL12/CXCR4 signaling in 
the bone marrow may result in a significant loss of bone marrow PCs
148
. In addition, IL-6 
produced by stromal cells has been identified as another important survival factor for memory 
PCs. Therefore, it is important to further dissect the stromal cell population and study their 
regulation of PCs, especially memory PCs in the bone marrow. 
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1.3.3. Memory B cells 
        Memory B cells are defined as cells that participate in a primary response and persist in the 
host after acute immune response. Memory B cells are normally in a resting state and do not 
express any effector functions, but upon secondary exposure to the memorized antigen, they 
quickly recognize them and produce a faster and stronger immune response
32
.  Memory B cells 
differentiate into antibody-secreting PCs upon reactivation, and they are more likely to undergo 
PC differentiation compared to naive B cells. Thus, chronic antigen exposure may persistently 
reactivate memory B cells to generate more antibody-secreting PCs, which is critical for the 
maintenance of long-lived humoral immunity
32
. 
        Memory B cells are highly diverse and multiple subsets have been discovered that may 
potentially carry different functions for the immune memory
32
. In humans, memory B cells were 
historically identified as immunoglobulin D
-
 (IgD
-
) B cells, as they had undergone class-switch 
recombination
177,178
. However, a later study identified another subset of IgD
+
 memory B cells
179
. 
To identify both types of human memory B cells, the same study provides a novel marker, the 
tumor necrosis factor (TNF) receptor family member CD27, which is also used nowadays to 
mark human memory B cells
179
. Being a general marker for memory B cells, CD27 cross-links 
CD70 to enhance B cell activation in vivo and to favor differentiation towards PCs, resulting in 
stronger antibody secretion
180-183
. CD27
+
 memory B cells can be further divided into IgM
- 
IgD
-
, 
IgM
+ 
IgD
+
 and IgM
+ 
IgD
-
 cells, and IgM
+
 memory cells respond faster to stimulation than naive 
cells
179,184,185
. In addition, more recent studies identify a new subset of memory B cells that are 
CD27
-
, and they are similar to CD27
+
 memory B cells for carrying somatically mutated 
immunoglobulin genes
186,187
. The identification of murine memory B cells is more complicated, 
as CD27 is not a marker for memory B cells in mice
188
. Due to the heterogeneity of memory B 
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cells, simply using surface markers may not provide an accurate method to identify them. A 
recent study used the immunization method to induce the production of memory B cells against a 
specific antigen, which can be identified by their capability to recognize the specific antigen and 
their expressions of conventional memory B cell markers
189
. 
        Memory B cells specific for vaccinia virus antigens (smallpox) have been discovered in 
humans even 50 years after immunization
190
. Multiple mechanisms have been shown or 
discussed for the maintenance of memory B cells
32
. A prior study suggests the requirement of an 
antigen for the maintenance of the antigen-specific memory B cells
191
. However, another study 
shows that phycoerythrin (PE) specific memory B cells are well persisted in nitrophenyl-chicken 
gamma globulin (NP-CGG) immunized mice that have not been exposed to PE
192
. Other than 
antigen dependency, survival and proliferation are other important mechanisms for memory B 
cell maintenance
32
. The spleen has been shown as a major reservoir of memory B cells against 
vaccinia virus
193
. In patients, circulating IgM
+
 IgD
+ 
CD27
+
 memory B cells rapidly decline and 
finally disappear after splenectomy
194
. Splenectomy also results in reduced, but not abrogated 
circulation of IgD
-
CD27
+
 memory B cells after 2 years, suggesting that while the spleen is an 
important reservoir for these memory B cells, other organs may also serve as their reservoirs
32
. 
Prior studies have also proposed the bone marrow as a reservoir for memory B cells
35,36
. 
Although a recent study suggests that only a small fraction of memory B cells are BM resident
34
, 
it is possible that these cells may carry unique functions. The bone marrow niche provides a 
microenvironment for the maintenance of long-term quiescent HSCs, thus it would be interesting 
to test whether these BM memory B cells are more quiescent and may survive in long term, and 
to study the potential mechanisms involved in the regulation of these memory B cells by the 
bone marrow niche. 
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1.4 Dendritic Cells 
1.4.1. cDC1  
        Classical DCs type 1 (cDC1s), also known as CD8α+ cDCs or CD103+ cDCs, were 
originally described as a subset of DCs in blood that express high levels of CD141 
(thrombomodulin, BDCA-3)
195-197
. Human cDC1s are a rare population among all cDCs, as they 
are only about one-tenth of cDC2s in steady-state blood and tissues
42,198-201
. cDC1s are found in 
both lymphoid and non-lymphoid tissues, and there are suggestions that they are more abundant 
in tissues compared to blood, although this idea may need further validation
42
. While sharing 
similar phenotypic markers with cDC2s, cDC1s may be distinguished by their low expression of 
CD11c, little expression of CD11b and SIRPα42. Besides, cDC1s express high levels of 
CLEC9A, CADM1 and BTLA
42
. Several gene expression studies have also identified XCR1 as a 
conserved marker for cDC1s in many species
202
. In addition, intracellular IRF8 expression may 
be used as a standard marker for identifying cDC1s, as unopposed expression of IRF8 (without 
IRF4) defines the lineage
198
. IRF8 is a transcription factor that play an important role to regulate 
the differentiation of DCs, especially cDC1s, at several stages during hematopoiesis through 
direct or indirect competition with transcription factors promoting other lineages
42,203
. IRF8 may 
limit granulocytic differentiation, balance DC to monocyte differentiation, compete with IRF4 to 
control cDC1:cDC2 output, and maintain cDC1 maturation
27,156
. Gene dosage of IRF8 is a 
critical determinant during DC development. Homozygous deletion of Irf8 causes loss of 
monocytes and all DCs, but excessive production of neutrophils
204,205
. Interestingly, subtle losses 
of IRF8 activity in mice only reduces the production of cDC1s
206
.  
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        Functionally, cDC1s have been characterized as a subset of DCs with a high intrinsic 
capacity to cross-present antigens via MHC I to activate CD8
+
 T cells and to release IL-12 to 
promote T helper type 1 (Th1) and natural killer responses
207-210
. Expression of XCR1 
chemokine receptor by cDC1s enables close interaction with XCL-producing activated T cells 
and nature killer (NK) cells
27
. Human cDC1s efficiently recognize viral and intracellular 
antigens, and transport antigens to the appropriate endosomal compartments through several 
conserved mechanisms
27,211
.  For example, cDC1s express high levels of CLEC9A, a unique 
receptor that recognizes bare actin filaments exposed upon necrotic cell death, thus directs cell-
associated antigens into the cross-presentation pathway
212-215
. cDC1s are also a major source of 
type III interferons (IFN), and the production and accumulation of these interferons during 
hepatitis C virus infection have been proposed to benefit viral clearance
216
. In mice, cDC1s have 
also been characterized as cross-priming tolerogenic cells, but this potential has not been well 
characterized in human
217,218
. 
 
1.4.2. cDC2 
        The majority of myeloid cDCs in different tissues and organs are characterized as classical 
DCs type 2 (cDC2s), also referred as CD11b
+
 cDCs, expressing CD1c, CD2, SIRPα and FcεR1 
42,197
. Similar to cDC1s, cDC2s also express myeloid surface markers CD13 and CD33, but high 
levels of CD11b and CD11c
27
. A prior transcriptional profiling study has also revealed 
CLEC10A, VEGFA and FCGR2A as surface markers of cDC2s
199
. There is great heterogeneity 
among cDC2s found in different tissues, and different subsets of cDC2s may be further 
characterized
27
. Recent studies have characterized human blood cDC2s into two subsets: one 
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subset being DC-like with higher expression of CD5, CD1c, HLA-DQ and IRF4; the other subset 
being monocyte-like expressing CD14, CD32, CD36 and proportionately higher MAFB
219,220
. 
The development of cDC2s may depend on multiple transcription factors, but unlike cDC1s or 
pDCs, no single transcription factor plays an exclusive role to regulate this process
197,221-223
. In 
mice, recent studies have identifed ZEB2 as a factor influencing the fate of pre-DCs towards the 
cDC2 lineage and IRF4 as a cDC2 lineage defining factor
198,222
. Subsets of murine cDC2s exist 
in diffent tissues and may depend on variable factors, such as RELB, NOTCH2 and KLF4
197
. In 
contrast, the regulation of cDC2 development in humans is different from mice, and is less 
understood.  In humans, heterozygous GATA2 deficiency leads to eventual loss of all cDC2s
221
. 
Deletion of IRF8 in humans abrogates entire DC development including cDC2s
204,205
, while 
cDC2s are IRF8-independent in mice
224
. 
        cDC2s express a wide range of lectins, TLRs, NOD-like receptors and RIG-I-like receptors, 
and may respond to intracellular pathogens, parasites, allergens, fungi and extracellular 
bacteria
27
. CD1a and CD1c expressed by cDC2s may present the glycolipid antigens of 
mycobacteria and other pathogens
225
. Dectin-1 and Dectin-2 are also highly expressed in tissue 
cDC2s, which are important for fungal recognition
226,227
. cDC2s may secrete IL-1, IL-8, IL-10, 
IL-12, IL-23 and tumor necrosis factor-α (TNF- α), but little type III interferons, which are 
mainly secreted by cDC1s
228,229
. In addition, in vitro studies have shown that human cDC2s 
could activate Type I T helper (Th1), Th2, Th17 and CD8
+
 T cells
182-230
. Thus, cDC2s have great 
potential to induce a wide range of immune responses in human.   
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1.4.3. pDC 
        Plasmacytoid DCs (pDCs) were first discovered in human tonsil and blood
231,232
. Different 
from myeloid cDCs, pDCs do not express CD11c, CD11b, CD13 or CD33
195,196,233
. Well-known 
markers for human pDCs include CD303 (CLEC4C or BDCA-2), CD304 (BDCA-4), CD85k 
(ILT3) and CD85g (ILT7), together with more recently characterized antigens FcεRI, BTLA, 
CD358 and CD300A
234,235
. Transcriptional profiling studies have also identified additional 
markers, FAM129C, CUX2 and GZMB
199
. Development of pDCs depend on the coordinated 
process of multiple transcription factors
42
. The key factors regulating the balance between pDC 
and cDC development are E2-2 (TCF4), a basic hemophagocytic lymphohistiocytosis protein, 
and its antagonist ID2, a DNA binding inhibitor
197,236
. TCF4 is the lineage-determining factor for 
pDCs and is negatively regulated by ID2
237
. Recent studies have described multiple transcription 
factors to regulate the relative production of pDCs and cDCs, through their interactions with the 
TCF4/ID2 signaling pathway
42
. In humans, heterozygous loss of Tcf4 results in Pitt–Hopkins 
syndrome with a pDC deficiency
42
.  
        Functionally, pDCs are specialized DCs that detect and respond to viral infections through 
the rapid production of large quantities of type I and type III interferons, and the secretion of 
cytokines
235,238
. Toll-like receptor 7 (TLR7) and TLR9 are key receptors for pDCs sensing 
single-stranded RNA and double-stranded DNA, respectively
235
. Interestingly, a prior study has 
revealed the potential of pDCs to sense self-nucleic acids
239
. Together with their prominent role 
in the production of type I interferon, pDCs have been implicated in the pathogenesis of 
autoimmune diseases including psoriasis and systemic lupus erythematosus
240,241
. Multiple 
studies have also suggested that pDCs are capable of priming CD4
+
 T cells and CD8
+
 T cells, 
although further studies may be necessary to evaluate their antigen-presenting capacity
42
. 
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Moreover, pDCs have been reported to play conflicting roles in allergy
242,243
. In addition, 
tolerogenic pDCs may be affected by granulocyte-macrophage colony-stimulating factor (GM-
CSF) to contribute to tumor progression
244
. 
 
1.5. Summary 
        The bone marrow niche is a complicated microenvironment that regulates HSPC 
maintenance and B lymphopoiesis. Prior studies have identified multiple cellular components of 
the bone marrow niche, including mesenchymal stem cells, endothelial cells, osteoblast lineage 
cells, megakaryocytes, macrophages, the sympathetic nervous system and mesenchymal stromal 
cells. Among these cellular components, mesenchymal stromal cells are particularly of our 
interest, which are heterogeneous and serve as the main source of multiple important soluble 
niche factors, such as CXCL12, SCF and IL-7. Prior studies in our lab have shown the 
importance of stromal CXCL12 expression on regulating B cell development in the bone 
marrow. Moreover, BM cDCs have been discovered in the bone marrow that may be important 
for the regulation of B cells, suggesting their potential involvement in the bone marrow niche. 
Further characterization of the heterogeneity of stromal cells, the role of CXCL12 expression in 
different stromal subsets and the role of BM cDCs in the regulation of HSPCs, will improve the 
overall understanding on the bone marrow niche and may provide potential targets for future 
clinical applications. 
        In Chapter 2, the heterogeneity of mesenchymal stromal cells will be studied by using 
different transgenic Cre models. In Chapter 3, the role of CXCL12 produced by different subsets 
of stromal cells will be assessed for their effects on B cell development, especially on the 
  
27 
 
maintenance of memory PCs and B cells. In Chapter 4, BM cDCs will be assessed for their 
effects on HSPCs by using ablation models, and the potential molecular mechanisms involved in 
their regulation of HSPCs will also be studied. Finally, in Chapter 5, these findings on the bone 
marrow niche and its regulation of HSPCs or B cells will be summarized and future directions 
will be outlined.  
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CHAPTER 2: TARGETING OF MESENCHYMAL STROMAL CELLS BY CRE-
RECOMBINASE TRANSGENES COMMONLY USED TO TARGET 
OSTEOBLAST LINEAGE CELLS 
 
2.1. Introduction 
        The bone marrow microenvironment contains a heterogeneous population of stromal cells 
that contribute to the regulation of hematopoiesis.  Identifying these stromal cells and the signals 
they generate has important clinical implications for a number of hematopoietic diseases
5,11
.  
Mesenchymal stromal cells implicated in the maintenance of hematopoietic stem cells (HSCs) 
include endothelial cells, osteoblasts, CXCL12-abundant reticular (CAR) cells, mesenchymal 
stem cells (MSCs), and arteriolar pericytes
3,4,10,12
.  The use of tissue-specific Cre-recombinase 
transgenes to delete genes of interest from defined stromal cell populations is an established and 
important technique in the field.  Rigorously defining the targeting specificity of the Cre-
recombinase transgenes is a key to the interpretation of such experiments.   
        Two Cre-recombinase transgenes that are commonly used to target osteolineage cells are 
Ocn-Cre and Dmp1-Cre.  Osteocalcin (Ocn, Bglap) is a secreted protein implicated in bone and 
glucose metabolism 
245
.  Cell culture and in situ expression studies show that OCN expression is 
mostly limited to osteoblasts and osteocytes
245,246
.  This has led to the widespread use of Ocn-
Cre transgenes to specifically target osteoblasts and osteocytes
247,248
.  Dentin matrix acidic 
phosphoprotein 1 (Dmp1) is expressed in odontoblasts, preosteocytes and osteocytes
249,250
.  
Indeed, a transgene containing an 8 kb regulatory region of Dmp1 linked to GFP results in 
osteocyte-specific GFP expression in the bone marrow
251
.  These data have led to the widespread 
use of Dmp1-Cre transgenes to specifically target osteocytes, although targeting of some 
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osteoblasts also has been observed
250,252,253
.  Furthermore, a study by Kalajzic et al showed that a 
10 kb Dmp1-Cre transgene targeted both osteoblasts and osteocytes, as well as a small 
population of undefined cells in the bone marrow 
250
.   
        In the present study, we used high-resolution microscopy of bone sections and flow 
cytometry to carefully define the targeting specificity of Ocn-Cre and Dmp1-Cre in the bone 
marrow.  We showed that both the Ocn-Cre and Dmp1-Cre transgenes target a much broader 
population of bone marrow stromal cells than previously appreciated.  We also characterized for 
the first time the spectrum of bone marrow stromal cells targeted by a Tagln-Cre transgene.  We 
show that Tagln-Cre efficiently targets osteoblasts and perivascular stromal cells, but not 
endothelial cells.   
 
2.2. Materials and Methods 
2.2.1. Mouse strains   
        Ai9 (B6.Cg-Gt(ROSA)26Sor
tm9(CAG-tdTomato)Hze
/J) 
254 
mice and Tagln-Cre (B6.129S6-
Tagln
tm2(cre)Yec
/J) mice were obtained from The Jackson Laboratory 
255
.  Ocn–Cre mice were a 
gift from Thomas Clemens (Johns Hopkins University, Maryland) 
256
. Cxcl12
gfp
 mice were a gift 
from Takashi Nagasawa (Kyoto University, Japan) 
257
,
 
and Dmp1-Cre mice (containing the 9.6 
kb murine Dmp1 promoter) were a gift from Roberto Civitelli (Washington University, MO) 
258
.  
All mice used in this study were 8-10 weeks old.  Both male and female mice were used equally 
in these studies.  Genotyping primers are listed in Suppl. Table 2.1.  Mice were maintained under 
SPF conditions, and all experimental procedures were performed according to methods approved 
by the Animal Studies Committee at Washington University.  
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2.2.2. Flow cytometry   
        Bone marrow cells were harvested from mouse femurs by first uncapping the ends of the 
bone and then centrifuging at 3300 x g for 5 minutes to expel the bone marrow contents.  These 
cells were then digested with 1.67 mg/ml of type II collagenase (Worthington) in phosphate-
buffered saline (PBS) for 12 minutes at 37 °C.  Of note, the majority of osteoblasts are not 
recovered using this procedure (Suppl. Fig 2.1).  The following antibodies were used: CD45 (30-
F11), CD31 (390), and Ter119 (TER-119). Cells were analyzed on a Gallios flow cytometer 
(Beckman Coulter), and data analysis was done using FloJo version 10.0.7 software (TreeStar).  
        To sort Dmp1-Cre targeted or non-targeted CAR cells, we first isolated platelet-derived 
growth factor receptor-beta (PDGFRβ)-positive stromal cells from the bone marrow of Dmp1-
Cre ROSA26
Ai9/+
 Cxcl12
gfp/+
 mice using the AutoMacs Pro Separator system (Miltenyi Biotec) 
and a biotinylated anti-PDGFRβ antibody (APB5).  Cells were incubated with antibodies against 
Gr-1 (RB6-8C5), PDGFRβ (APB5), CD45 (30-F11), CD31 (390), and Ter119 (TER-119) and 
then incubated with brilliant violet 421-conjugated Streptavidin (405225, BioLegend). CAR cells 
were identified as Cxcl12-GFP
bright
 PDGRRβ+ Gr1- CD45- CD31- Ter119- cells.  Dmp1-Cre 
targeted CAR cells were tdTomato
high
. Cells were sorted using a MoFlo high-speed flow 
cytometer (Dako Cytomation).  All antibodies were obtained from eBioscience, unless otherwise 
noted.   
 
2.2.3. Immunostaining of bone sections   
        Mouse hindlimbs were fixed in PBS containing 4% paraformaldehyde, pH 7.4, for 24 hours 
at 4 °C.  Bones were then decalcified in PBS containing 14% EDTA, pH 7.4, for 7 days at 4 °C.  
Following incubation in PBS containing 30% sucrose for 24 hours at 4 °C, bones were 
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embedded in Optimal Cutting Temperature Compound (Sakura Finetek).  These tissue blocks 
were cut into 12 μm sections using a Leica Cryo-Jane system (Leica Biosystems).  For 
immunostaining, the slides were blocked with 10% donkey serum, diluted in 0.1M Tris-Cl pH 
7.5, 150 mM NaCl, and 0.1% Tween 20 (TNT) buffer for 1 hour at room temperature.  
Following blocking using the Avidin/Biotin Blocking Kit (SP-2001, Vector Laboratories), slides 
were then incubated in primary antibody overnight at 4 °C and, where applicable, they were 
incubated with secondary antibody for 1 hour at room temperature.  The following antibodies 
were used: rabbit anti-NG2 (AB5320, EMD Millipore), rat anti-Sca1 (557403, BD Biosciences), 
goat anti-VECadherin (AF1002, R&D Systems), mouse anti-αSMA (1A4, Sigma Aldrich); 
AlexaFluor 488-conjugated donkey anti-rat IgG (Jackson Immunoresearch); DyLight649-
conjugated donkey anti-rat IgG (Jackson Immunoresearch); and biotin-conjugated donkey anti-
goat IgG (Jackson Immunoresearch).  In some cases, slides were then incubated with 
streptavidin-DyLight 649 (Jackson Immunoresearch) for 1 hour at room temperature.  Finally, 
slides were mounted with ProLong Gold antifade reagent with DAPI (Life Technologies).  
Images were acquired with a LSM 700 microscope (Carl Zeiss) and processed using Volocity 
software (PerkinElmer).  
        For Hematoxylin & Eosin (H&E) staining, bone sections were air dried for 1 hour and then 
incubated with Hematoxylin Gill #3 (GHS316, Sigma-Aldrich) for 5 minutes followed by 
incubation with Eosin (HT110132, Sigma-Aldrich) for 3 minutes. Sections were then fixed by 
serial five-minute incubations in 50%, 70%, 95%, and 100% ethanol, followed by a five-minute 
incubation in xylene.  Finally, slides were mounted with Permount mounting medium (Fisher 
Chemical). Images were acquired with a LSM 700 microscope (Carl Zeiss). 
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2.2.4. RNA expression profiling  
        RNA was purified from sorted CAR cells using the Qiagen RNeasy Micro Kit (74004, 
Qiagen).  Libraries were generated using the NuGen Pico SL kit (NuGEN Technologies, San 
Carlos, CA) and then hybridized to Affymetrix Mouse Gene 1.0 ST arrays (Affymetrix, Santa 
Clara, CA). Gene set enrichment was performed using the GSEA software (Broad Institute). 
Differences in gene expression were determined using Significance Analysis of Microarrays 
(SAM; Stanford University, Stanford, CA).  Expression data has been submitted to Gene 
Expression Omnibus, record number GSE81399. 
 
2.2.5. Statistical analyses   
        Unpaired t-test was used to evaluate the significance of differences between two groups. All 
data are presented as mean ± S.D. 
 
2.3. Results 
2.3.1. Ocn-Cre targets osteoblasts, a majority of CAR cells, and arteriolar pericytes   
        To characterize the targeting specificity of Ocn-Cre in postnatal mouse bones, we generated 
Ocn-Cre ROSA26
Ai9/+
 mice and Ocn-Cre ROSA26
Ai9/+
 Cxcl12
gfp/+ 
mice.  The Cxcl12
gfp/+ 
transgene allows for the identification of CXCL12-GFP
bright
 (CAR) cells, which are perivascular 
stromal cells in the bone marrow implicated in HSC maintenance 
4
.  The ROSA26
Ai9/+
 transgene 
allows for the identification of Ocn-Cre targeted tdTomato
+ 
cells.  Immunostaining of the bone 
sections confirmed that the Ocn-Cre transgene efficiently targets osteoblasts (Fig. 2.1A & B, 
Suppl. Fig. 2.2) 
256
.  Surprisingly, we also observed that Ocn-Cre targets a substantial fraction of 
CXCL12-GFP
bright
 cells (Fig. 2.1A & C).  Of note, as expected, no tdTomato
+ 
CAR cells were 
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detected in control (Cxcl12
gfp/+
) mice (Suppl. Fig. 2.3). Flow cytometry showed that Ocn-Cre 
targets 72.2 ± 4.0% (n = 3 mice) of CXCL12-GFP
bright
 cells (Fig. 2.1D). To assess targeting of 
arteriolar pericytes, we stained bone sections from wild type mice with antibodies against alpha-
smooth muscle actin (αSMA) and NG2 (Fig. 2.2A & B).  In these assays, arteriolar endothelial 
cells were identified by Sca1
12
, which is also expressed on hematopoietic stem/progenitor cells 
but not on CAR cells 
3.  Whereas αSMA staining was limited to a subset of arteriolar pericytes, 
NG2 staining was observed in all arteriolar pericytes (Fig. 2.2A & B).  Accordingly, all αSMA-
positive arteriolar pericytes co-expressed NG2, while only 56.9 ± 11.1% (n = 3 mice) of NG2-
positive arteriolar pericytes co-expressed αSMA.  Immunostaining of bone sections from Ocn-
Cre ROSA26
Ai9/+
 mice showed that Ocn-Cre targets 72.2 ± 13.3% (n = 3 mice) of NG2-postive 
arteriolar pericytes (Fig. 2.2C). Thus, in addition to osteoblasts, Ocn-Cre targets the majority of 
CAR cells and arteriolar pericytes in mice.  
 
2.3.2. Dmp1-Cre targets osteoblasts and a subset of CAR cells   
        To characterize the targeting specificity of Dmp1-Cre in postnatal mouse bones, we 
generated Dmp1-Cre ROSA26
Ai9/+
 mice and Dmp1-Cre ROSA26
Ai9/+
 Cxcl12
gfp/+
 mice.  As 
reported previously
253,258
, the Dmp1-Cre transgene efficiently targets all osteoblasts (Fig. 2.3A & 
B, Suppl. Fig. 2.4).  Surprisingly, Dmp1-Cre also targets a subset of CAR cells (Fig. 2.3A & C).  
Interestingly, Dmp1-Cre targeted CAR cells were not enriched near the endosteum or 
osteoblasts, but were distributed throughout the bone marrow (Suppl. Fig. 2.5A & B).  By flow 
cytometry 29.2 ± 1.7% (n = 3 mice) of CAR cells are targeted by Dmp1-Cre (Fig. 2.3D).   In 
contrast to Ocn-Cre, NG2
+
 arteriolar pericytes were rarely targeted by Dmp1-Cre (Fig. 2.3 E).  
Thus, Dmp1-Cre targets all osteoblasts and a subset of CAR cells but few arteriolar pericytes.   
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        To characterize the Dmp1-Cre targeted subset of CAR cells, we sorted tdTomato
+
 (Dmp1-
Cre targeted) and tdTomato
-
 CAR cells (non-targeted) and performed RNA expression profiling.   
Gene set enrichment analysis showed that Dmp1-Cre targeted CAR cells were highly enriched 
for a previously identified group of genes involved in osteoblast maturation or bone development 
(Suppl. Fig. 2.6A).  Indeed, expression of genes associated with mature osteoblasts such as 
Bglap2 (Ocn) and Postn (periostin) are increased nearly 4-fold compared to non-targeted CAR 
cells (Fig. 2.3F).  In contrast, expression of early osteoblast lineage genes, including Sp7 
(osterix) and Runx2 were normal or only minimally elevated (Fig. 2.3F).  Expression of key HSC 
maintenance genes (Cxcl12, Kitl, and Angpt1) or key B lymphoid factor genes (Igf1, Flt3l, or 
BAFF) was similar in Dmp1-Cre targeted and non-targeted CAR cells (Suppl. Fig. 2.6B & C).  
However, expression of interleukin-7, which is required for pro-B cell maintenance, was 
significantly reduced in Dmp1-Cre targeted CAR cells. 
 
2.3.3. Tagln-Cre targets osteoblasts, a majority of CAR cells, and both arteriolar and 
venous sinusoidal pericytes  
        Arteriolar pericytes have been implicated in HSC maintenance and can be readily identified 
in the bone marrow as Nestin-GFP
bright
 or NG2
+
 periarteriolar cells
12
.  However, a recent study 
reported that a substantial number of functional HSCs localize to venous sinusoids in the central 
bone marrow
159
.  In an effort to better visualize and isolate sinusoidal pericytes, we tested 
targeting by the Tagln-Cre transgene.  Tagln encodes for transgelin (SM22a) and is expressed in 
smooth muscle cells and cardiomyocytes
259-261
.  Tagln is also expressed in osteoblasts
262
.  
Accordingly, Tagln-Cre targets all osteoblasts (Fig. 2.4A & B, Suppl. Fig. 2.7).  Analyzing 
Tagln-Cre ROSA26
Ai9/+
 Cxcl12
gfp/+ 
mice, we observed that Tagln-Cre and CXCL12-GFP mark 
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overlapping, but distinct, bone marrow stromal cell populations (Fig. 2.4B & C).  Whereas 
Tagln-Cre targets the great majority of CXCL12-GFP
+
 CAR cells that line venous sinusoids 
which are marked by VE-cadherin
12,13
, it does not efficiently target those CXCL12-GFP
+
 CAR 
cells that are not in direct contact with sinusoids (Fig. 2.4D, yellow arrows).  Conversely, Tagln-
Cre targets a population of perisinusoidal cells that are CXCL12-GFP
-
dim/negative (Fig. 2.4D, 
red arrows), presumably representing non-CAR venous pericytes.  Moreover, Tagln-Cre, but not 
CXCL12-GFP, marks periarteriolar pericytes (Fig. 2.4E).  Indeed, Tagln-Cre targeted nearly all 
NG2
+
 arteriolar pericytes (Fig.  2.4E & F).  Flow cytometry showed that Tagln-Cre targets 74.9 
± 5.2% (n = 3 mice) of CAR cells (Fig. 2.4G).  Conversely, 16.6 ± 2.3% (n = 3 mice) of Tagln-
Cre targeted stromal cells were CXCL12-GFP dim/negative.  Collectively, these data show that 
Tagln-Cre efficiently targets all osteoblasts, a majority of CAR cells and both venous and 
arteriolar pericytes.   
 
2.4. Discussion 
        Ocn-Cre has been widely used to target osteoblasts in past studies 
245,247,248
. Our data show 
that Ocn-Cre targets not only osteoblasts, but also more than 70% of CAR cells and arteriolar 
pericytes. CAR cells are mesenchymal progenitors that have adipogenic and osteogenic capacity 
in vitro 
263
.  However, only a small subset of CAR cells contributes to osteoblast development in 
vivo 
4
.  Whether the Ocn-Cre targeted subset of CAR cells is fated to osteoblast differentiation is 
unclear.  Of note, we did not observe preferential localization of Ocn-Cre targeted CAR cells to 
the endosteal region.  CAR cells constitutively produce high levels of multiple cytokines and 
chemokines that regulate hematopoiesis, including CXCL12 and stem cell factor 
263
.  Indeed, 
CAR cells have been implicated in the maintenance of HSCs and B lymphoid progenitors 
264,265
.  
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Thus, phenotypes reported using Ocn-Cre need to be interpreted in light of our data showing 
targeting of CAR cells and arteriolar pericytes, in addition to osteoblasts.         
        Dmp1-Cre has been widely used to target osteocytes 
250,252,266
.  Several Dmp1-Cre 
transgenes have been described.  In this study, we show that the 10 kb Dmp1-Cre transgene, not 
only efficiently targets osteoblasts, but also a subset of CAR cells.  The results are consistent 
with a prior study by Kalajzic et. al. showing that the 10 kb Dmp1-Cre transgene targets a small 
population of undefined cell in the bone marrow, in addition to osteoblasts and osteocytes 
250
.  Of 
note, the same group also reported that an 8 kb Dmp1-Cre transgene, which is thought to be 
more osteocyte restricted, targets, at least a subset of, osteoblasts 
250
.  Whether the 8 kb Dmp1-
Cre transgene targets a subset of CAR cells will require further study.  Our data show that the 10 
kb Dmp1-Cre transgene targets approximately 30% of CAR cells.  Expression profiling of this 
subset of CAR cells shows higher expression of genes associated with mature osteoblasts, 
suggesting that Dmp1-Cre targeted CAR cells may be enriched for osteoprogenitors.  Functional 
studies are needed to confirm this possibility.   
        We report for the first time the spectrum of bone marrow stromal cells that are targeted by a 
Tagln-Cre transgene.  Prior studies in non-bone tissues had shown transgelin expression in 
cardiomyocytes and vascular smooth muscle cells 
259-261
.  Consistent with its expression in 
osteoblasts 
262
, Tagln-Cre efficiently targets osteoblasts.  Interestingly, Tagln-Cre appears to 
target a majority of CAR cells.  Specifically, it targets those CAR cells that are closely associated 
with venous sinusoids (i.e., venous sinusoidal pericytes).  Conversely, Tagln-Cre does not 
efficiently target CAR cells that are more distant from sinusoids.  Finally, Tagln-Cre efficiently 
targets arteriolar pericytes, which, despite evidence for high CXCL12 expression 
12
, do not 
express high-level GFP in Cxcl12
gfp
 mice.  Thus, the Tagln-Cre represents an important new tool 
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for investigators to efficiently target both venous sinusoidal and arteriolar pericytes in the bone 
marrow.  
        This study highlights the complexity and heterogeneity of mesenchymal stromal cells in the 
bone marrow.  Nestin-GFP
+
, LepR
+
, and CAR cells represent overlapping but not identical 
populations of perivascular mesenchymal stromal cells 
4,10,21,265
.  Bulk cell analysis of each of 
these populations shows high-level expression of genes that regulate hematopoiesis, including 
factors that regulate HSCs (e.g., kit ligand) and B lymphopoiesis (e.g., interleukin-7) 
4,21,264,265
.  
Our study suggests that there is considerable heterogeneity within the CAR cell population.  For 
example, the Dmp1-Cre targeted subset of CAR cells, in addition to being enriched for osteoblast 
genes, expresses a lower level of interleukin-7 (IL-7).  IL-7 producing stromal cells in the bone 
marrow are required for the maintenance of Pro-B cells 
264
, suggesting that Dmp1-Cre targeted 
CAR cells likely don’t contribute this specific stage of B cell development.   
        In summary, we have rigorously defined the targeting specificities in the bone marrow for 
the three Cre-recombinase transgenes.  Ocn-Cre and Dmp1-Cre target broader stromal cell 
populations than previously appreciated, and this data should be incorporated in the design of 
future studies.  These data further highlight the heterogeneity of mesenchymal stromal cells in 
the bone marrow, and suggest that the Cre-recombinase transgenes used in this study could be 
used to interrogate this heterogeneity. 
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2.7. Figures 
 
Figure 2.1. Ocn-Cre targets osteoblasts and a majority of CAR cells.  (A) Composite image 
of H & E stained sections from the femur of an Ocn-Cre ROSA26
Ai9/+
 mouse.  (B) Representative 
photomicrographs of the metaphyseal region (region “a” in panel A) of a femur section stained 
for osteocalcin (green) to mark osteoblasts and DAPI (blue) to highlight nuclei; cells that had 
undergone Cre-mediated recombination express tdTomato (red). (C) Representative 
photomicrographs taken from the diaphyseal region (similar to region “b” in panel A) of a femur 
section from an Ocn-Cre ROSA26
Ai9/+
 Cxcl12
gfp/+
 mouse.   Cells that express CXCL12 also 
express GFP (green).  Counterstaining with DAPI highlights nuclei (blue).  (D) Representative 
dot plots showing GFP and tdTomato expression in lineage (CD45, CD31 and Ter119) negative 
stromal cells harvested from Ocn-Cre ROSA26
Ai9/+
 Cxcl12
gfp/+
 mice.  Original magnification, 
200X except for panel A, which is 100X.   
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Figure 2.2. Ocn-Cre targets the majority of arteriolar pericytes.   Representative 
photomicrographs of the diaphyseal region (similar to region “b” in Fig. 1A) of a femur section 
from a wild type mouse stained for αSMA (red), NG2 (green), Sca1 (white) and DAPI (blue). 
(A) Images showing αSMA+ NG2+ arteriolar pericytes around Sca1+ arteriolar endothelial cells. 
(B) Images showing αSMA- NG2+ arteriolar pericytes around Sca1+ arteriolar endothelial cells. 
(C) Representative photomicrographs of the diaphyseal region of a femur section from an Ocn-
Cre ROSA26
Ai9/+
mouse stained for NG2 (green) and DAPI (blue). TdTomato (red) represents 
cells targeted by Ocn-Cre.  Original magnification, 200X.  
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Figure 2.3. Dmp1-Cre targets all the osteoblasts and a subset of CAR cells but no arteriolar 
pericytes. (A) Composite image of H & E stained sections from the femur of a Dmp1-Cre 
ROSA26
Ai9/+
 mouse. (B) Representative photomicrographs of the metaphyseal region (region “a” 
in panel A) of a femur section that was stained for osteocalcin (green) and DAPI (blue). Dmp1-
Cre targeted cells express tdTomato (red). (C) Representative photomicrographs taken from the 
diaphyseal region (similar to region “b” in panel A) of a femur section from a Dmp1-Cre 
ROSA26
Ai9/+
 Cxcl12
gfp/+
 mouse; cells that express CXCL12 also express GFP (green).  (D) 
Representative dot plot showing GFP and tdTomato expression in lineage (CD45, CD31 and 
Ter119) negative stromal cells harvested from Dmp1-Cre ROSA26
Ai9/+
 Cxcl12
gfp/+
 mice.  (E) 
Representative photomicrographs taken from the diaphyseal region of a femur section from a 
Dmp1-Cre ROSA26
Ai9/+
 Cxcl12
gfp/+
 mouse stained for NG2 (green) and DAPI (blue). (F) RNA 
expression profiling of sorted Dmp1-Cre targeted (tdTomato
+
) or non-targeted (tdTomato
-
) CAR 
cells was performed.  Shown are probe signals for the indicated genes (n = 3 mice).  All data 
represent the mean ± S.D. *P < 0.05; **P < 0.01 (unpaired t-test). Original magnification, 200X 
except for panel A, which is 100X.   
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Figure 2.4. Tagln-Cre targets osteoblasts, a majority of CAR cells, and both venous 
sinusoidal and arteriolar pericytes.  (A) Composite image of H & E stained sections from the 
femur of a Tagln-Cre ROSA26
Ai9/+
 mouse. (B) Representative photomicrographs of the 
metaphyseal region (region “a” in panel A) of a femur section that was stained for osteocalcin 
(green) and DAPI (blue).  (C) Representative photomicrographs taken from the diaphyseal 
region (similar to region “b” in panel A)  of a femur section from a Tagln-Cre ROSA26Ai9/+ 
Cxcl12
gfp/+
 mouse stained for VE-cadherin (white) to mark all endothelial cells; cells that express 
CXCL12 also express GFP (green). (D) Enlarged images of the boxed region in panel C. (E) 
Representative photomicrographs taken from the diaphyseal region of a femur section from a 
Tagln-Cre ROSA26
Ai9/+
 Cxcl12
gfp/+
 mouse stained for Sca1 (white) to mark arteriolar endothelial 
cells. (F) Representative photomicrographs taken from the diaphyseal region of a femur section 
from Tagln-Cre ROSA26
Ai9/+
 mouse stained for NG2 (green) to mark arteriolar pericytes. (G) 
Representative dot plot of lineage (CD45, CD31 and Ter119) negative stromal cells from a 
Tagln-Cre ROSA26
Ai9/+
 Cxcl12
gfp/+
 mouse showing GFP and tdTomato expression.  Original 
magnification, 200X except for panel A, which is 100X.   
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2.8. Supplementary Figures 
 
 
Supplementary Figure 2.1.  Osteoblasts remain attached to bone following centrifugation of 
femurs. Representative photomicrographs of a femur section from an Ocn-Cre ROSA26
Ai9/+
 
mouse obtained after centrifugation to expel bone marrow contents.  Ocn-Cre targeted cells 
express tdTomato (red). TdTomato
+
 cells lining bone are identified as osteoblasts. Nuclei are 
highlighted with DAPI (blue). Original magnification, 200X. 
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Supplementary Figure 2.2. Ocn-Cre efficiently targets osteoblasts. Composite image of 
representative photomicrographs from an Ocn-Cre ROSA26
Ai9/+
 mouse. Cells that have 
undergone Cre-mediated recombination express tdTomato (red); DAPI (blue) highlights nuclei. 
Tdtomato
+
 cells lining bone are identified as osteoblasts.  Original magnification, 100X for all 
images.  
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Supplementary Figure 2.3. Immunostaining of Ocn-Cre Cxcl12
gfp/+
 bone sections. 
Representative photomicrographs taken from the diaphysis of a femur section from an Ocn-Cre 
Cxcl12
gfp/+
 mouse.  GFP (left panel) and tdTomato (right panel) fluorescent signals are shown.  
Note, as expected, no tdTomato
+
 CAR cells are seen in these mice.  Original magnification, 
200X for all images. 
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Supplementary Figure 2.4. Dmp1-Cre efficiently targets osteoblasts. Composite image of 
representative photomicrographs from a Dmp1-Cre ROSA26
Ai9/+
 mouse. Cells that had 
undergone Cre-mediated recombination express tdTomato (red); DAPI (blue) highlights nuclei. 
Tdtomato
+
 cells lining bone are identified as osteoblasts.  Original magnification, 100X for all 
images.  
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Supplementary Figure 2.5. Distribution of Dmp1-Cre targeted CAR cells. (A) Composite 
image of representative photomicrographs of a femur section from a Dmp1-Cre ROSA26
Ai9/+
 
Cxcl12 
gfp/+
 mouse (upper left panel). Dmp1-Cre targeted cells express tdTomato (red). Cells that 
express CXCL12 also express GFP (green). Counterstaining with DAPI highlights nuclei (blue).  
Higher magnifications of the highlighted regions are shown in the upper right and lower left 
panels.  Original magnification, 100X for all images. (B) Percentage of Dmp1-Cre targeted and 
non-targeted CAR cells within a specified distance from the closest osteoblast (OB). Data 
represent the mean ± S.D.  n = 3 mice. 
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Supplementary Figure 2.6. RNA expression profiling of Dmp1-Cre targeted CAR cells. 
Dmp1-Cre targeted (tdTomato
+
) and non-targeted CAR cells (tdTomato
-
) were sorted from 
Dmp1-Cre ROSA26
Ai9/+
 Cxcl12
gfp/+
 mice and RNA expression profiling was performed (n=3 
mice). (A) Left panel is the gene set enrichment analysis (GSEA) plot showing enrichment for a 
previously identified group of osteoblast-lineage genes (p<0.001, FDR = 0.009). The right panel 
is a heat map for each gene in this group; red represents higher and blue represents lower 
expression. Samples “Dmp1 1, 2 and 3” represent Dmp1-Cre targeted CAR cell samples, while 
“CAR 1, 2 and 3” represent non-targeted CAR cell samples. (B) Expression of key genes 
associated with HSC maintenance.  (C) Expression of key genes that support B lymphopoiesis.  
All data are presented as mean ± S.D. *, p-value < 0.05 (unpaired t-test).  
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Supplementary Figure 2.7. Tagln-Cre efficiently targets osteoblasts. Composite image of 
representative photomicrographs from a Tagln-Cre ROSA26
Ai9/+
 mouse. Cells that have 
undergone Cre-mediated recombination express tdTomato (red); DAPI (blue) highlights nuclei. 
Tdtomato
+
 cells lining bone are identified as osteoblasts.  Original magnification, 100X for all 
images. 
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2.9. Supplementary Table 
Primers for the detection of generic Cre transgene in Ocn-Cre and Dmp1-Cre mice. 
 Primer Name Primer Sequence (5’ -> 3’) 
Cre FOR GCATTACCGGTCGATGCAACGAGTGATGAG 
Cre REV GAGTGAACGAACCTGGTCGAAATCAGTGCG 
 
Primers for the detection of Cxcl12
 gfp 
transgene. 
Primer Name Primer Sequence (5’ -> 3’) 
CXCL12-GFP FOR GGACTGGGAAGATCAAAGGTC 
CXCL12-GFP mutant REV GAACTTCAGGGTCAGCTTGC 
CXCL12-GFP wt REV GGTGGACCGAGAGTGAAAGT 
 
Primers for the detection of ROSA26
Ai9 
transgene. 
Primer Name Primer Sequence (5’ -> 3’) 
Ai9 wt FOR AAGGGAGCTGCAGTGGAGTA 
Ai9 wt REV CCGAAAATCTGTGGGAAGTC 
Ai9 mutant REV GGCATTAAAGCAGCGTATCC 
Ai9 mutant FOR CTGTTCCTGTACGGCATGG 
 
Primers for the detection of the Tagln-Cre transgene. 
Primer Name Primer Sequence (5’ -> 3’) 
Tagln-Cre FOR GGCCCAGGGGTTGTCAAAATAGTC 
Tagln-Cre wt REV CTCCTCCAGCTCCTCGTCATACTTC 
Tagln-Cre mutant REV CGCCGCATAACCAGTGAAACAG 
 
Supplementary Table 2.1. Primers for genotyping transgenic mice in this study. “FOR” 
means forward primer and “REV” means reverse primer. “mutant” represents the primers used 
for the detection of a transgene and “wt”  represents the primers used for the detection of the 
wild type allele at the corresponding locus for that transgene.  
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CHAPTER 3: CXCL12 FROM OCN-CRE TARGETED BONE MARROW 
STROMAL CELLS REGULATES LATE-STAGE B CELL DEVELOPMENT 
 
3.1. Introduction 
        CXCL12 is a common chemokine found in the bone marrow that is important for the 
regulation of B lymphopoiesis. CXCL12 interacts with its main receptor, CXCR4, to activate 
multiple signaling pathways responsible for the control of chemotaxis, cell proliferation and cell 
survival
20,169,170
.  In the bone marrow, mesenchymal stromal cells, especially CAR cells are the 
main source of CXCL12
3,10
. CAR cells are a heterogeneous population and previous studies have 
tested multiple transgenic Cre mouse models for targeting different subsets of CAR cells
3,19
. 
Among these Cre models, Prx1-Cre and Osx-Cre target nearly all CAR cells, while Prx1-Cre 
targets additional mesenchymal stem cells
3
. In contrast, Ocn-Cre and Dmp1-Cre targets around 
70% and 30% of CAR cells, respectively
19
. A prior study has suggested the specific role of 
Dmp1-Cre targeted CAR cells as being enriched for potential osteoprogenitors, but the specific 
functions of Ocn-Cre targeted CAR cells have not yet been discussed
19
.  
        In humans and mice, B lymphopoiesis mainly occurs in the bone marrow, with the 
additional requirement of peripheral lymphoid organs
23
. B cell development undergoes a 
stepwise progression of stages which can be identified based on surface marker expression
24
. 
Hardy Fractions have been extensively used to identify different stages of B cells, and Fraction F 
describes the last stage of B cell development before maturation, the mature naive B cells that 
express IgD
26,28-30
. In response to stimulation, such as antigen exposure, mature B cells will 
further differentiate into anti-body secreting plasma cells (PCs) or memory cells
32
. Memory cells 
may include memory B cells and memory PCs, also known as long-lived PCs, both have been 
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suggested to potentially reside in the bone marrow
32-36
. So far, only limited research has been 
done to study the functions and regulations of mature naive B cells, memory B cells and memory 
PCs in the bone marrow. 
        In the present study, we used different transgenic Cre models to test the regulation of B cell 
development by CXCL12 from different subsets of stromal cells. We show that CXCL12 
expressed by Ocn-Cre targeted stromal cells may be specifically important for the regulation of 
mature naive B cells and memory B cells in bone marrow. Collectively, data from this study may 
provide insight into the complex relationships between different stromal cell populations and 
may improve our understanding of the regulation of B lymphopoiesis and immune memory in 
the bone marrow by CXCL12.  
 
3.2. Materials and Methods 
3.2.1. Mouse strains 
        Cxcl12flox mice were generated as previously described3. Prx1-Cre (B6.Cg-Tg(Prrx1-
cre)1Cjt/J) mice, Osx-Cre (B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J) mice, CAG-GFP 
(Tg(CAG-GFP*)1Hadj/J) mice, IgHa/J (B6.Cg-Gpi1
a
 Thy1
a
 Igh
a
/J) mice and Ai9 (B6.Cg-
Gt(ROSA)26Sor
tm9(CAG-tdTomato)Hze
/J) 
254 
mice were obtained from The Jackson Laboratory 
255
.  
Ocn–Cre mice were a gift from Thomas Clemens (Johns Hopkins University, Maryland) 256. 
Cxcl12
gfp
 mice were a gift from Takashi Nagasawa (Kyoto University, Japan) 
257
,
 
and Dmp1-Cre 
mice (containing the 9.6 kb murine Dmp1 promoter) were a gift from Roberto Civitelli 
(Washington University, MO) 
258
.  Cxcl12
+/-
 mice were obtained through the RIKEN 
BioResource Center (Ibaraki, Japan). All mice used in this study were 8-10 weeks old. Both male 
and female mice were used equally in these studies.  Mice were maintained under SPF 
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conditions, and all experimental procedures were performed according to methods approved by 
the Animal Studies Committee at Washington University.  
 
3.2.2. Immunostaining of bone sections 
        Femurs and tibias were harvested from mice and fixed overnight in 10% formalin (Sigma-
Aldrich) at 4
o
C. Fixed bones were then washed twice in PBS, followed by decalcification in 14% 
ethylenediaminetetraacetic acid (EDTA) pH 7.4 solution for 7 days. Decalcified bones were then 
incubated  in 30% sucrose in PBS overnight at 4
o
C. These bones were then snap frozen in 
optimum cutting temperature (OCT) medium (Tissue-Tek) in Cryomold (Tissue-Tek). Frozen  
blocks were sectioned using the Cryostat system (Leica Biosystems). Sections were then 
processed using standard immunofluorescent staining protocol. Antibodies used for 
immunofluorescent staining included: goat anti-mouse VE-Cadherin (R&D Systems AF1002), 
rat anti-mouse IgD (BD Biosciences clone 11-26c.2a), rat anti-mouse B220 (BD-Biosciences, 
RA3-6B2), and rat anti-mouse IgM (eBioscience II/4). In the end, slides were mounted with 
Prolong Gold Antifade Reagent (Invitrogen) and were sealed with nail polish. Slides were 
imaged using a LSM 700 confocal microscope and ZEN imaging software (Zeiss). 
 
3.2.3. Flow Cytometry 
        Bone marrow cells were harvested from mouse femurs by first uncapping the ends of the 
bone and then centrifuging at 3300 x g for 5 minutes to expel the bone marrow contents. Spleen 
cells were harvested from mouse spleen by crushing spleen and filter the cells through a 22um 
strainer. Cells were stained by standard protocols with the following antibodies (eBiosciences 
unless otherwise noted): CD3e (145-2C11), CD4 (L3T4), CD8a (53-6.7), CD11b (M1/70), 
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CD45R (RA3-6B2, B220), CD11c (N418), Flk2 (A2F10), CD27 (LG.7F9), Gr-1 (RB6-8C5, 
BioLegend), IL-7Ra (gift of Deepta Bhattacharya, Washington University), Ly6D (49-H4, BD 
Biosciences), NK1.1 (PK136), IgM (II/4), IgD (11-26c), CD19 (eBio1D3), CD43 (S7, BD 
Biosciences), TER-119, CD45 (30-F11), CD31 (390), CD80 (16-10A1, BioLegend), CCR6 (29-
2L17, BioLegend). NP (4-Hydroxy-3-nitrophenylacetyl hapten) (Biosearch Technologies) was 
conjugated with Allophycocyanin (APC) to form NP-APC (gift of Deepta Bhattacharya, 
Washington University). Cells were analyzed on a Gallios flow cytometer (Beckman Coulter), 
and data analysis was done using FloJo version 10.0.7 software (TreeStar).  
 
3.2.4. Quantitative real-time PCR 
        To collect total bone marrow RNA, tibias from mice were flushed with 1 mL of Trizol 
(Invitrogen) and RNA was extracted following the manufacturer’s instructions. cDNA was 
prepared using iScript cDNA Synthesis Kit (Bio-Rad). Quantitative real-time PCR (qRT-PCR) 
was then performed using the TaqMan Universal RT Master Mix (Applied Biosystems), with no 
template and no RT controls. Data was collected on a OneStep Real-Time PCR System (Applied 
Biosystems). Primers were:  
CXCL12 forward, 5’GAGCCAACGTCAAGCATCTG-3’; 
CXCL12 reverse, 5’-CGGGTCAATGCACACTTGTC-3’;  
CXCL12 dT-FAM/TAMRA probe, 5’-TCCAAACTGTGCCCTTCAGATTGTTGC-3’;  
β-actin forward, 5’-ACCAACTGGGACGATATGGAGAAGA-3’;  
β-actin dT-VIC/TAMRA probe, 5′-AGCCATGTACGTAGCCATCCAGGCTG-3′. 
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3.2.5. Mature B cell homing assay  
        Spleens were harvested from 8-12 week old CAG-GFP mice, and were then crushed and 
filtered through a 22um cell strainer. 5 million splenocytes were injected into Cxcl12
flox/-
 or Ocn-
Cre: Cxcl12
flox/-
 mice, through retro-orbital injection. Recipient mice were then harvested 24 
hours after transplantation to collect bone marrow and spleen using the same method as 
described earlier. GFP
+
 mature naive B cell number was quantified via flow cytometry. 
 
3.2.6. Primary and secondary immunization 
        Ocn-Cre:Cxcl12
flox/flox
 or Cxcl12
flox/flox
 mice were immunized with a mixture of 100µg NP-
CGG (Chicken Gamma Globulin) (Biosearch Technologies) and 100µl of aluminium hydroxide 
gel adjuvant (Alhydrogel) (InvivoGen), through intraperitoneal injection. The enzyme-linked 
immunosorbent assay (ELISA) was then performed to test primary immune response. Immune 
memory was measured 2 weeks after primary immunization. For secondary immunization, 20 
million donor cells from NP-CGG immunized Ocn-Cre:Cxcl12
flox/flox
 or Cxcl12
flox/flox
 mice were 
transplanted into IgHa/J recipient mice without irradiation, through retro-orbital injection. One 
day after transplantation, 50µg of NP-CGG was injected into these recipient mice, through retro-
orbital injection. Secondary immune response was then measured with ELISA. 
 
3.2.7. Enzyme-linked immunosorbent assay (ELISA) 
        ELISA plates were coated with 5µg/ml NP (18)-BSA protein, or 5µg/ml BSA as control, 
overnight at 4 ºC. Then, block the ELISA plates with ELISA blocking buffer (PBS + 2%BSA + 
0.05% Tween20) at 37 ºC for 1 hour. Wash plates, add diluted serum samples, serially diluted 
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standard controls or negative controls into ELISA plates, incubate at room temperature for 2 
hours. For primary immune response, add anti-mouse IgM antibody (Life Technologies) and 
incubate at room temperature for 1 hour. Wash plates, then add HRP-goat anti-mouse IgM (Life 
Technologies) and incubate at room temperature for 1 hour. Then, develop the plate in TMB 
solution (eBioscience) and stop the reaction with stop buffer (eBioscience). Read the plates at 
450nm wavelength, using an Epoch Microplate Spectrophotometer (BioTek).  
        For measuring secondary immune response, after incubating the plate with serially diluted 
serum samples, add biotinylated anti-IgG1b (BD Pharmingen) or biotinylated anti-IgG1a (BD 
Pharmingen) antibodies into the plates, incubate at room temperature for 1 hour. Wash plates, 
add streptavidin-HRP (BD Pharmingen), incubate at room temperature for 1 hour. Then, use the 
same protocol as for measuring primary immune response to develop the plates. 
 
3.2.8. Statistical analyses         
        Statistical significance was determined using Prism software (GraphPad). Unless otherwise 
indicated, unpaired t-test or 1/2-way ANOVA analyses were used to evaluate the significance of 
differences between two or multiple groups. All data are presented as mean ± SEM. 
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3.3. Results 
3.3.1. Ocn-Cre targeted stromal cells regulate mature naive B cells in bone marrow 
        To assess the role of CXCL12 expressed by different subsets of bone marrow stromal cells 
in B cell lymphopoiesis, we previously crossed different transgenic Cre models with Cxcl12
flox/-
 
mice (experiments done by Ryan Day). Prx1-Cre was used to ablate CXCL12 from nearly all 
bone marrow stromal cells as it targets mesenchymal stem cells and their downstream progeny, 
including CAR cells, osteoblasts and osteocytes
3
. As expected, ablation of CXCL12 in Prx1-Cre 
targeted stromal cells significantly reduced the mRNA level of CXCL12 to a minimal level in 
the bone marrow (Fig. 3.1A). Meanwhile, we observed significant decrease in white blood cells 
(WBCs) and all stages of B cells during B lymphopoiesis in the bone marrow (Fig. 3.1B-J). Osx-
Cre was used to target CAR cells and their downstream progeny, including osteoblasts and 
osteocytes
3
. Ablation of CXCL12 in Osx-Cre targeted stromal cells resulted in a significant 
reduction of CXCL12 mRNA level, but to a lesser extent compared to Prx1-Cre:Cxcl12
flox/-
 
model (Fig. 3.1A). Similar to Prx1-Cre:Cxcl12
flox/-
 mice, we observed significant decrease in 
WBCs and total B cells, as well as in other stages during B cell development, except in common 
lymphoid progenitors (CLPs) and B lymphoid restricted progenitors (BLPs) (Fig. 3.1B-J). This is 
consistent with our previous finding that CXCL12 expressed by Prx1-Cre targeted mesenchymal 
stem cells is important for the development and maintenance of CLPs and BLPs
3
. Ocn-Cre 
targets ~70% of CAR cells, all osteoblasts and arteriolar pericytes
19
. Interestingly, ablation of 
CXCL12 in Ocn-Cre targeted cells resulted in a mild, but non-significant reduction of CXCL12 
mRNA level (Fig. 3.1A). Moreover, Ocn-Cre:Cxcl12
flox/-
 mice showed no significant decrease of 
WBCs, total B cells and most stages of B cell development, except mature naive B cell or 
Fraction F cells (Fig. 3.1B-J). To address the question whether the mild decrease of CXCL12 in 
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Ocn-Cre:Cxcl12
flox/-
 mice may affect mature naive B cells, we further examined Prx1-
Cre:Cxcl12
flox/+
 mice. Our data shows that the two models have nearly the same expression 
levels of CXCL12, but Ocn-Cre:Cxcl12
flox/-
 mice have a significantly lower number of mature 
naive B cells (Fig. 3.1K&L). Collectively, these data suggests that CXCL12 from Ocn-Cre 
targeted cells may play a specific role in the regulation of mature naive B cells in the bone 
marrow. 
        To more specifically assess the role of CXCL12 expressed by Ocn-Cre targeted cells, we 
further generated Ocn-Cre:Cxcl12
flox/flox
 mice. In these mice, we observed a significant, but mild 
reduction of CXCL12 mRNA level, compared to Cxcl12
flox/flox
 control mice (Fig. 3.2A). 
Meanwhile, we observed significant decrease of mature naive B cells, while other stages of B 
cell development remain unchanged (Fig. 3.2B). Dmp1-Cre targets ~30% of CAR cells, all 
osteoblasts and few arteriolar pericytes
19
. In Dmp1-Cre:Cxcl12
flox/flox
 mice, we observed no 
significant decrease in CXCL12 mRNA level and all stages of B cell development (Fig. 
3.2C&D). Comparing data from Dmp1-Cre:Cxcl12
flox/flox
 and Ocn-Cre:Cxcl12
flox/flox
 mice, it 
suggests that the expression of CXCL12 by osteoblasts plays little role in the regulation of 
mature naive B cells, and Ocn-Cre targeted stromal cells specifically regulate mature naive B 
cells through their expression of CXCL12.  
 
3.3.2. CXCL12 expression in Ocn-Cre targeted stromal cells regulates the homing and/or 
retention of mature naive B cells in the bone marrow 
        Mature naive B cells were mostly developed in the spleen and some of them home back to 
the bone marrow
26,28-30
. In Ocn-Cre:Cxcl12
flox/-
 mice, the number of mature naive B cells in the 
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spleen was comparable to the Cxcl12
flox/-
 control mice (Fig. 3.3A). This observation suggests that 
the loss of mature naive B cells in the bone marrow of Ocn-Cre:Cxcl12
flox/-
 mice is not likely due 
to a defect in peripheral maturation. To examine the homing and/or retention of mature naive B 
cells in the bone marrow, we transplanted splenocytes from CAG-GFP donor mice that 
ubiquitously express GFP into Ocn-Cre:Cxcl12
flox/-
 mice or Cxcl12
flox/-
 control mice (Fig. 3.3B). 
After 24 hours, the recipient mice were harvested and the number of GFP
+
 mature naive B cells 
was quantified in both bone marrow and spleen, using flow cytometry (Fig. 3.3C&D). While 
there was no significant difference in spleen (Fig. 3.3C), the number of GFP
+
 mature naive B 
cells was significantly reduced in the bone marrow of Ocn-Cre:Cxcl12
flox/-
 mice (Fig. 3.3D). 
Collectively, these data demonstrate that CXCL12 expression in Ocn-Cre targeted stromal cells 
plays an important role in the regulation of homing and/or retention of mature naive B cells in 
the bone marrow.  
 
3.3.3. Ablation of CXCL12 in Ocn-Cre targeted stromal cells did not affect bone marrow 
plasma cells and primary immune response 
        Other than Hardy fractions of B cells during different developmental stages, plasma cells 
(PCs) and memory B cells, two terminal stage B cells have also been found in the bone 
marrow
32,35,36
. To assess the effects of stromal CXCL12 ablation on plasma cells in the bone 
marrow, femurs from Ocn-Cre:Cxcl12
floxflox-
 mice and Cxcl12
flox/flox
 control mice were harvested 
and analyzed. Using flow cytometry, we discovered no significant difference after stromal 
CXCL12 ablation, for the numbers of IgM
+
 or IgG
+
 PCs, defined as B220
+
 CD138
+
 cells (Fig. 
3.4A&B). To functionally assess the effects of stromal CXCL12 ablation on PCs, we examined 
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the humoral immunity after antigen exposure in the two groups of mice. Ocn-Cre:Cxcl12
floxflox-
 
mice and Cxcl12
flox/flox
 control mice were immunized with NP-CGG (1:19 ratio), and we 
quantified the humoral immune response by measuring the amount of NP-specific IgM 
antibodies in blood serum using ELISA. At different time points, we found no significant change 
on the NP-specific IgM levels in blood serum after stromal CXCL12 ablation (Fig. 3.4C). 
Collectively, these data suggests that the ablation of CXCL12 in Ocn-Cre targeted stromal cells 
does not affect the number of PCs in the bone marrow and the humoral immunity. 
 
3.3.4. Ablation of CXCL12 in Ocn-Cre targeted stromal cells reduces the number of 
memory B cells in the bone marrow 
        To assess the effects of CXCL12 ablation in Ocn-Cre targeted stromal cells on memory B 
cells, we immunized Ocn-Cre:Cxcl12
floxflox-
 mice and Cxcl12
flox/flox
 control mice with NP-CGG 
(1:19 ratio). Two months after immunization, we quantified the number of NP-specific memory 
B cells in the bone marrow using flow cytometry. NP-specific memory B cells were defined as 
NP
+
 Lin
-
 B220
+
 IgM
-
 IgD
-
 CCR6
+
 CD80
+
 cells, and we observed a significant reduction of the 
memory B cells when CXCL12 was ablated in the bone marrow (Fig. 3.5A). In addition, we 
quantified the number of NP-specific memory B cells in the spleen from the same mice and 
found no significant differences (Fig. 3.5B). Collectively, these data demonstrates the 
importance of CXCL12 expressed by Ocn-Cre targeted stromal cells in the regulation of memory 
B cells in the bone marrow.  
        To our surprise, a population of NP
+
 Lin
-
 B220
+
 IgM
+
 IgD
+
 CCR6
+
 CD80
+
 cells was found 
in the bone marrow whose number was decreased in Ocn-Cre:Cxcl12
floxflox-
 mice, compared to 
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Cxcl12
floxflox-
control mice (Fig. 3.5C). Same population was also found in the spleen, but had no 
decrease when stromal CXCL12 was ablated (Fig. 3.5D). The potential existence of IgM
+
 IgD
+
 
memory B cells was previously discussed by other studies
179,184,185
. To test whether these cells 
may carry similar functions as the conventional memory B cells that are IgM
-
 IgD
-
, we assessed 
the secondary immune response generated from these cells. Wildtype mice were immunized with 
NP-CGG to generate memory B cells and we collected unenriched cells, IgM
+
 and IgD
+
 enriched 
cells (including IgM
+
 IgD
+
 cells), and IgM
-
 IgD
-
 enriched cells from these mice at 2 months post 
immunization. All three samples of cells were then transferred into IgHa/J recipient mice through 
retro-orbital injection, followed by secondary immunization of NP-CGG one day after transplant. 
IgHa/J mice only express IgG1a but not IgG1b which is the only isotype expressed by the donor 
mice. One week after secondary immunization, ELISA was used to quantify the amount of NP-
specific IgG1b in these recipient mice to estimate the secondary immune response generated 
from the donor memory cells. Our preliminary data showed that IgM
+
 and IgD
+
 enriched cells 
from both bone marrow and spleen could not generate significant secondary immune response, 
suggesting IgM
+
 IgD
+
 cells play little role in the B cell immune memory (Fig. 3.5E).   
  
3.4. Discussion 
        We have previously shown the importance of CXCL12 in the regulation of B lymphopoiesis 
in the bone marrow
3
. We have demonstrated the requirement of CXCL12 expression from 
mesenchymal stem cells for the maintenance of CLPs and BLPs, while CXCL12 expression from 
CAR cells are not required for early B lymphopoiesis until pre-pro-B cell stage
3
. This study 
further characterizes the role of CXCL12 expression from different subsets of stromal cells on B 
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lymphopoiesis. Our data shows that CXCL12 expression from Ocn-Cre targeted cells are 
specifically important for the maintenance of mature naive B cells. We also ablated CXCL12 in 
Dmp1-Cre targeted cells and found no effects on mature naive B cells or other B cell 
compartments. A prior study has shown that both Ocn-Cre and Dmp1-Cre targets nearly all 
osteoblasts, and about 70% or 30% of CAR cells, respectively
19
. Moreover, Ocn-Cre, but not 
Dmp1-Cre, targets arteriolar pericytes
19
. Thus, CXCL12 expression by Ocn-Cre targeted stromal 
cells, but not osteoblasts, regulates mature naive B cells. To further understand this regulation, 
we examined the homing and/or retention of mature naive B cells in Ocn-Cre:Cxcl12
flox/-
 mice, 
and observed a significant defect, compared to the control mice.  
        In addition, we also examined the effects of CXCL12 ablation in Ocn-Cre targeted stromal 
cells on two end-stage B cells, plasma cells and memory B cells in the bone marrow. We 
observed no significant decrease of plasma cells in Ocn-Cre:Cxcl12
flox/flox
 mice, while IgM
-
 IgD
-
 
 
NP-specific memory B cells were significantly reduced. To confirm this finding, further 
experiments will be performed to test whether there is a functional defect of NP-specific immune 
memory in the bone marrow. Interestingly, we also discovered an IgM
+
 IgD
+  
NP-specific B cell 
population in the bone marrow, expressing similar markers as the conventional memory B cells. 
To test the function of these cells, we performed secondary immunization and assessed the 
secondary immune response generated by these cells. Our data suggests that these cells play little 
role in the generation of secondary immune response, and their functions remain unclear.  
        In conclusion, our data show that CXCL12 expression by Ocn-Cre targeted stromal cells 
may specifically regulate mature naive B cells and memory B cells. This study provides further 
evidence to support the functional heterogeneity of bone marrow mesenchymal stromal cells, 
which may improve our knowledge on the regulation of the bone marrow niche. Meanwhile, 
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better understanding of the regulation of B lymphopoiesis and B cell derived immune memory 
may provide targets with clinical relevance, contributing to the development of potential 
therapies against different diseases involved in the bone marrow.   
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3.7. Figures 
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Figure 3.1 CXCL12 expression by stromal cells is important for B lymphopoiesis. A. 
Cxcl12
flox/-
(flox/-), Ocn-Cre:Cxcl12
flox/-
 (Ocn flox/-), Osx-Cre:Cxcl12
flox/-
 (Osx flox/-) and Prx1-
Cre:Cxcl12
flox/-
 (Prx1 flox/-) mice were flushed with Trizol to extract total bone marrow RNA, 
which was then used for RT-qPCR. mRNA level of CXCL12 was normalized to β-actin. B-J. 
Femurs from four groups of transgenic mice were harvested and analyzed for different cells 
populations using flow cytometry. Cell populations include: white blood cell (WBC) (B), 
common lymphoid progenitor (CLP) (C), B lineage restricted progenitor (BLP) (D), total B cell 
(E), pre-pro B cell (F), pro-B cell (G), pre-B cell (H), immature B cell (I) and mature naive B 
cell (J). Sample size, n = 5-37 mice per group in all experiments. K&L. Prx1-Cre:Cxcl12
flox/+
 
(Prx1 flox/+) mice were also examined and compared with Ocn flox/- group for CXCL12 
expression (K) (n = 7 or 12 mice, respectively) and the number of mature naive B cells (L) (n = 
10 or 21 mice, respectively). Data represent the mean ± SEM, *P < 0.05; **P < 0.01; ***P < 
0.001; ****P<0,0001; “ns” means non-significnat, compared to Cxcl12flox/- control mice unless 
otherwise indicated. 
 
 
 
 
 
 
 
  
68 
 
 
Figure 3.2. CXCL12 expression in Ocn-Cre targeted stromal cells is important for the 
regulation of mature naive B cells. A&C. Tibias from A. Ocn-Cre:Cxcl12
flox/flox
 (Ocn-
flox/flox), C. Dmp1-Cre:Cxcl12
flox/flox
 (Dmp1-flox/flox), and Cxcl12
flox/flox
 (flox/flox) mice were 
flushed with Trizol to extract total bone marrow RNA, which was then used for RT-qPCR. 
mRNA level of CXCL12 was normalized to β-actin. B&D. Femurs were harvested from Ocn-
Cre:Cxcl12
flox/flox
 mice (B), Dmp1-Cre:Cxcl12
flox/flox
 mice (D), and Cxcl12
flox/flox
 control mice 
(B&D). Bone marrow from the femurs were then analyzed using flow cytometry to quantify the 
number of B cells during different developmental stages. Sample size, n = 3-6 mice per group in 
all experiments.  Data represent the mean ± SEM, **P < 0.01; ***P < 0.001, compared to 
Cxcl12
flox/flox
 control mice unless otherwise indicated. 
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Figure 3.3. CXCL12 expression in Ocn-Cre targeted stromal cells regulates the homing 
and/or retention of mature naive B cells in the bone marrow. A. The number of mature naive 
B cells in the spleen from Cxcl12
flox/-
(flox/-) and Ocn-Cre:Cxcl12
flox/-
 (Ocn flox/-) mice, were 
quantified using flow cytometry. B. 5 x 10
6
 splenocytes from CAG-GFP mice were transplanted 
into Cxcl12
flox/-
 and Ocn-Cre:Cxcl12
flox/-
 recipient mice through retro-orbital injection, and the 
bone marrow from femurs were harvested and analyzed at 24 hours after injection. C&D. The 
numbers of GFP
+
 mature naive B cells in the bone marrow (C) and spleen (D) were quantified 
using flow cytometry. Sample size, n = 11-16 mice per group in all experiments. Data represent 
the mean ± SEM, *P < 0.05, compared to Cxcl12
flox/-
 control mice unless otherwise indicated. 
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Figure 3.4. Ablation of CXCL12 in Ocn-Cre targeted stromal cells had no effects on plasma 
cells (PCs) and primary immune response. A&B. The number of IgM
+ 
PCs (A) and IgG
+ 
PCs 
(B) were quantified by flow cytometry in Ocn-Cre:Cxcl12
flox/flox
 and Cxcl12
flox/flox
 mice (n = 6 
mice per cohert). C. Ocn-Cre:Cxcl12
flox/flox
 and Cxcl12
flox/flox
 mice were immunized with NP-
CGG and the amount of NP-specific IgM antibodies were quantified at different time points (n = 
5 mice per cohert).  Data represent the mean ± SEM.  
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Figure 3.5. Ablation of CXCL12 in Ocn-Cre targeted stromal cells reduces the 
number of memory B cells in the bone marrow. Ocn-Cre:Cxcl12flox/flox and Cxcl12flox/flox 
mice were immunized with NP-CGG. A&B. Two months later, Np-specific IgM
-
 IgD
-
 
conventional memory B cells were quantified in the bone marrow (A) and the spleen (B) of these 
mice by flow cytometry. C&D.  Np-specific IgM
+
 IgD
+
 memory-like B cells were quantified in 
the bone marrow (C) and the spleen (D) of the same mice (n = 6 or 8 mice per cohert). Wildtype 
mice were immunized with NP-CGG. Two months later, unenriched cells, IgM
+
 and IgD
+
 
enriched cells, and IgM
-
 IgD
-
 enriched cells were collected from both the bone marrow and the 
spleen of these mice. All of these cells were separately transferred into IgHa/J recipient mice 
through retro-orbital injection, followed by secondary NP-CGG immunization one day after 
transplant. E. The amount of NP-specific IgG1b in blood serum was quantified one week later 
using ELISA, which was represented by light absorbance. Data represent the mean ± SEM, **P 
< 0.01; ***P < 0.001, compared to Cxcl12
flox/flox
 control mice unless otherwise indicated. 
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CHAPTER 4: CLASSICAL DENDRITIC CELLS IN BONE MARROW 
REGULATE HEMATOPOIETIC STEM AND PROGENITOR CELL 
TRAFFICKING THROUGH CXCR2 SIGNALING IN SINUSOIDAL 
ENDOTHELIAL CELLS 
 
4.1. Introduction 
        A resident population of classical dendritic cells (cDCs) has been identified in murine bone 
marrow, but its contribution to the regulation of hematopoiesis and establishment of the stem cell 
niche is largely unknown
49
.  Here, we show that murine bone marrow cDCs are perivascular and 
have a cDC2-like immunophenotype.  A similar population of cDCs is present in human bone 
marrow.  RNA expression analysis of sorted BM cDCs showed that expression of many 
chemokines and chemokines receptors is distinct from that observed in splenic cDC2s, 
suggesting that BM cDCs may represent a unique DC population.   Ablation of cDCs results in 
hematopoietic stem/progenitor cell (HSPC) mobilization that is greater than that seen with 
ablation of bone marrow macrophages.  Ablation of cDCs is associated with an expansion of 
bone marrow endothelial cells and increased vascular permeability.  CXCR2 expression in 
sinusoidal endothelial cells and the expression of two CXCR2 ligands, CXCL1 and CXCL2, in 
the bone marrow are markedly increased following BM cDC ablation.  Treatment of endothelial 
cells in vitro with CXCL1 induced increased permeability and transmigration of HSPCs.  
Finally, we show that HSPC mobilization after BM cDC ablation is attenuated in mice lacking 
CXCR2 expression.  Collectively, these data suggest that BM cDCs play an important role in 
regulating HSPC trafficking, at least in part, through its regulation of sinusoidal CXCR2 
signaling and vascular permeability.  
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4.2. Material and Methods 
4.2.1. Mouse strains  
         The CX3CR1
gfp/+
 mice were a gift from D. Littmann
267
 (New York University School of 
Medicine).  Zbtb46
dtr 
(B6(Cg)-Zbtb46
tm1(HBEGF)Mnz
/J), Zbtb46
gfp
 (129S-Zbtb46
tm1Kmm
/J), Col2.3-
GFP (B6.Cg-Tg(Col1a1*2.3-GFP)1Rowe/J) and CXCR2
-/-
 (C.129S2(B6)-Cxcr2
tm1Mwm
/J) 
mice were obtained from The Jackson Laboratory.  CD169
dtr
 mice were a gift from Y. 
Obata
268,269
 (Riken BioResource Center, Ibaraki, Japan). CD169
dtr
 mice were bred with Zbtb46
dtr
 
mice to generate CD169
 dtr
:Zbtb46
dtr
 mice. Sex- and age-matched mice were used in all 
experiments.  All mice were inbred on a C57BL/6 background except Zbtb46
gfp
 mice, which 
were on a mixed C57BL/6 and 129 SvEv background. The numbers of animals used per 
experiment are stated in the figure legends. Mice were maintained under SPF conditions, and all 
experimental procedures were performed according to methods approved by the Animal Studies 
Committee at Washington University.   
 
4.2.2. Generation of bone marrow chimeras 
        Six to eight weeks old wild-type Ly5.1/Ly5.2 recipient mice were irradiated with two 550 
cGy doses, 6 hours apart. Two million donor bone marrow cells were then injected retro-
orbitally.  Mice were placed on prophylactic antibiotics (trimethoprim-sulfamethoxazole) for 2 
weeks following the first dose of irradiation. Mice were analyzed eight weeks after 
transplantation. 
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4.2.3. Diphtheria toxin administration 
        Diphtheria toxin (D0564, Sigma) was diluted in PBS containing 0.1% low-endotoxin 
bovine serum albumin and administered intraperitoneally at a dose of 200 ng/day for up to 6 
days. 
 
4.2.4. CFU-C assays 
        Cells obtained from the bone marrow, peripheral blood, and spleen were analyzed using a 
Hemavet (Drew Scientific) automated cell counter. 40 μL of peripheral blood, 2.5 × 104 bone 
marrow cells, or 1.0 × 10
5
 splenic cells were plated in 3mL Mouse Methylcellulose Complete 
Media (HSC007, R&D Systems).  Cultures were plated in duplicate in 60 mm petri dishes and 
incubated in a humidified chamber with 5% CO2 at 37°C. The number of colonies per dish was 
counted on day 7. 
 
4.2.5. Flow cytometry  
        Bone marrow, spleen and peripheral blood were processed for flow cytometry as previously 
described
270
. Cells were analyzed on a Gallios flow cytometer (Beckman Coulter) or sorted on a 
Sony SY3200 “Synergy” high-speed cell sorter (Sony). Data analysis was done using FloJo 
version 10.0.7 software (TreeStar). The following antibodies were used for staining murine cells: 
Gr-1 (RB6-8C5), CD19 (1D3), CD48 (BCM1), B220 (RA3-6B2), CD3e (17A2), Ter119 (TER-
119), Sca-1 (D7), CD117 (2B8), CD115 (AFS98), CD45 (30-F11), CD45.1 (A20) and CD45.2 
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(104) from eBiosciences; CD31 (390), F4/80 (BM8), I-A/I-E (M5/114.15.2), CD11c (N418), 
CD150 (TC15-12F12.2), CD169 (3D6.112), CD11b (M1/70) and XCR1 (ZET) from BioLegend. 
        For cell sorting, classical dendritic cells from bone marrow and spleen were both identified 
as CX3CR1-GFP
high
 B220
-
 Gr-1
-
 MHCII
high
 CD11c
high
 F4/80
+
 cells. Endothelial cells were 
identified as Lineage
-
 (CD45
-
 Ter119
-
 Gr-1
-
) CD31
+
 cells with Sca1
+
 to mark arteriolar and Sca1
-
 
to mark sinusoidal endothelial cell.  
        For staining human bone marrow cells, the following antibodies were used: CD3 (555332), 
CD15 (555401), CD19 (555412) and CD11c (B-ly6) from BD Biosciences; CD13 (WM-15), 
CD20 (2H7) and CD56 (MEM188) from eBiosciences; CD33 (P67.6), CD1c (L161), CD14 
(M5E2), CD141 (M80) and HLA-DR (L243) from BioLegend. 
 
4.2.6. Immunostaining of bone sections 
        Mouse hindlimbs were processed for immunostaining as previously described
19
. The 
following antibodies were used: chicken anti-GFP (ab13970, Abcam), rat anti-MHCII (107601, 
BioLegend), Rat anti-Sca1 (557403, BD Biosciences), goat anti-VECadherin (AF1002, R&D 
Systems), and anti-B220 (12-0452-83, EBioscience); AlexaFluor 488 donkey anti-rat IgG 
(Invitrogen), AlexaFluor 488 donkey anti-chicken IgG (Jackson Immunoresearch), and biotin-
conjugated donkey anti-goat IgG (Jackson Immunoresearch]).  In some cases, slides were then 
incubated with streptavidin-DyLight 649 (Jackson Immunoresearch) for 30 minutes at room 
temperature. Finally, slides were mounted with ProLong Gold antifade reagent with DAPI (Life 
Technologies).  Images were acquired with an LSM 700 microscope (Carl Zeiss), and images 
were processed using Volocity software (PerkinElmer). 
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4.2.7. Real-time quantitative RT-PCR 
        Mouse femurs were flushed with 1 mL of TRIzol reagent (Invitrogen), and RNA was 
isolated according to the manufacturer’s instructions. Reverse transcription was performed using 
iScript™ cDNA Synthesis Kit (Bio-Rad) according to the manufacturer’s instructions. 
Quantitative PCR was performed using iTaq™ Universal Probes Supermix (Bio-Rad) on a 
StepOne Plus Real-Time PCR System (Applied Biosystems). RNA content was normalized to 
mouse β-actin. Primer and probes for mouse β-actin (Mm01324804_m1), CXCL12 
(Mm00445553_m1), CXCL1 (Mm04207460_m1), and CXCL2 (Mm00436450_m1) were 
ordered from ThermoFisher. 
 
4.2.8. RNA expression profiling 
        RNA was purified from sorted classical dendritic cells (cDCs) and endothelial cells using 
the Qiagen RNeasy Micro Kit (74004, Qiagen).  For cDC RNA samples, libraries were generated 
using the NuGen Pico SL kit (NuGEN Technologies, San Carlos, CA) and then hybridized to 
Affymetrix Mouse Gene 1.0 ST arrays (Affymetrix, Santa Clara, CA). Gene set enrichment was 
performed using the GSEA software (Broad Institute). Differences in gene expression were 
determined using Significance Analysis of Microarrays (SAM; Stanford University, Stanford, 
CA).  Expression data has been submitted to Gene Expression Omnibus, record number. 
 
4.2.9. In vitro permeability test and cell migration assay 
       Human Umbilical Vein Endothelial Cells (HUVECs) (S200-05N, Sigma) were cultured in 
Endothelial Cell Growth Medium (211-500, Sigma) at 37ºC, 5% CO2. 2×10
5
 HUVECs were pre-
  
78 
 
cultured in the upper chamber of the Boyden Chamber system for 24 hours to form a HUVEC 
layer. During the same time, the HUVEC layer was pre-treated with 40ng/ml recombinant 
CXCL1 (453-KC-010/CF, Thermo Fisher) or PBS as control. 
To test permeability of the HUVEC layer for large molecules, 400µl Endothelial Cell Growth 
Medium containing 100µg/ml Evan’s blue was added to the upper chamber of the cell insert with 
0.4µm pores in the membrane (141078, Thermo Fisher). 1ml of Hank balanced salt solution 
(H6648-500ML, Sigma) was added to the bottom chamber. After 1 hour incubation at 37ºC, 5% 
CO2, Evan’s blue in the bottom chamber was measured by light absorbance at 620nm using 
Epoch 2 microplate spectrophotometer (Biotek), and the amount of Evan’s blue was calculated 
using a standard curve. Amount of Evan’s blue in the CXCL1 treated samples were normalized 
to the amount in the PBS treated control samples for comparison. 
To test permeability of the HUVEC layer for cell migration, 400µl medium containing ~5×10
4
 
human CD34
+
 cells were added to the upper chamber of the cell insert with 3µm pores in the 
membrane (141080, Thermo Fisher). Human CD34
+
 cells were enriched from primary human 
bone marrow donated by healthy donors, using CD34 MicroBead Kit (130-100-453, Miltenyi 
Biotec) and autoMACS Pro Separator (Miltenyi Biotec). 1ml of medium containing 100ng/ml 
recombinant CXCL12 (578702, BioLegend) was added to the bottom chamber. Meanwhile, 
CXCL1 or PBS was added to the appropriate samples to continue the pre-treatment. After 24 
hour incubation at 37ºC, 5% CO2, number of cells migrated to the bottom chamber was 
quantified and the percentage was calculated.   
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4.2.10. Statistical analyses         
        Statistical significance was determined using Prism software (GraphPad). Unless otherwise 
indicated, unpaired t-test or 1/2-way ANOVA analyses were used to evaluate the significance of 
differences between two or multiple groups. All data are presented as mean ± SEM. 
 
4.3. Results 
4.3.1. Classical dendritic cells (cDCs) are enriched in the perivascular region and may be 
functionally specific for the perivascular niche. 
        Dendritic cells (DCs) are a component of the innate immune system and are distributed 
throughout the body.  DCs are professional antigen presenting cells that contribute to immune 
cell activation through the secretion of cytokines and chemokines.  DCs display considerable 
phenotypic and functional heterogeneity, suggesting that DCs in specific tissues may have 
evolved to perform distinct functions
37-39
.  DCs include classical DCs (cDCs) with dendritic 
morphology and outstanding capacity for presenting antigens and priming T cells,  and 
plasmacytoid DCs (pDCs) which are lymphocyte-like cells specialized in the production of type 
I interferons
40,41,43
. cDCs may be further divided into type 1 cDCs (cDC1s), mainly against 
viruses, tumors and intracellular pathogens, and type 2 cDCs (cDC2s), mainly agaisnt parasites, 
allergens, extracellular bacteria and fungi
42
. A prior study identified a resident population of 
cDCs in the bone marrow and provided evidence that these cells promote the survival of 
circulating mature B cells in the bone marrow
49
.  To better characterize BM cDCs, we developed 
a multicolor flow cytometry to analyze myeloid cell populations in Cx3cr1
gfp/+ 
mice, which 
express high levels of green fluorescent protein (GFP) in monocytes and BM cDCs, but not in 
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bone marrow macrophages
7,267
.  Monocytes were identified as CX3CR1-GFP
high
 MHC II
low
 
B220
-
/CD19
-
 cells (Fig. 4.1a), and, consistent with prior studies, expressed F4/80 but were 
mostly negative for CD11c and CD169 (Fig. 4.1b)
271,272
.  Bone marrow macrophages were 
identified as CX3CR1-GFP
low
, MHC II
+
, B220
-
/CD19
-
 cells and expressed CD169 and F4/80, 
but little CD11c.  Finally, BM cDCs were identified as CX3CR1-GFP
high
 and MHC II
high
 B220
-
/CD19
-
 cells.  As expected, BM cDCs expressed a high level of CD11c and F4/80, but a low 
level of CD169
51
. cDCs represent 0.048 ± .017% of nucleated cells in mouse bone marrow 
compared to 0.096 ± .047% for macrophages (n = 11 mice).  A prior study showed that BM 
cDCs are perivascular, although this study did not distinguish between venous sinusoids and 
arterioles
49
.  We show that the great majority of CX3CR1-GFP
high
 and MHC II
high
 DCs in the 
bone marrow are perivascular (Fig. 4.1c: iv-viii), with the majorit
venous sinusoid or arteriole (Fig. 4.1d, e).  
        To further characterize mouse BM cDCs, we assessed their expression of XCR1 and CDllb, 
which are selectively expressed on cDC1s and cDC2s, respectively
42
.  Nearly all of the cDCs 
express CD11b but not XCR1, suggesting that the majority of murine BM DCs are cDC2-like 
cells (Fig. 4.1f).  We next examined bone marrow from healthy donors to determine whether 
cDCs also are present in human bone marrow.  Indeed, the percentage of cDCs in human bone 
marrow (0.076 ± .041%, n = 3 donors) was similar to that seen in murine bone marrow.  
Moreover, the majority of cDCs in human bone marrow express CD1c but not CD141, consistent 
with a cDC2-like phenotype (Fig. 4.1g)
42
.  RNA expression profiling was performed on sorted 
murine BM cDCs and compared to prior data generated using splenic cDC2 cells.  Surprisingly, 
the patterns of gene expression for chemokines and chemokine receptors were strikingly 
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different, suggesting that BM cDCs may represent a unique dendritic cell population with 
distinct functional properties (Fig. 4.1h). 
  
4.3.2. BM cDC ablation induces a loss of macrophage and HSPC mobilization 
        To assess their functional importance, BM cDCs were ablated using CD11c
dtr
 mice.  A prior 
study showed that treatment with diphtheria toxin (DT) results in efficient ablation of cDCs in 
the bone marrow, but it is also associated with systemic toxicity leading to death
273,274
. As 
reported previously
275
, to circumvent DT-induced lethality, we transplanted bone marrow from 
CD11c
dtr
 mice into irradiated wild-type congenic recipients (Supplemental Fig. 4.1a).  Treatment 
of CD11c
dtr
 bone marrow chimeras with DT did not affect the number of HSPCs in the bone 
marrow (Fig. 2a, Supplemental Fig. 4.1b), but resulted in a modest HSPC mobilization into 
spleen and blood (Fig. 2b,c, Supplemental Fig. 4.1c), as quantified by CFU-C and C-kit
+
 Sca1
+
 
Lin
- 
(KSL) marked HSPCs. Prior studies have shown that CD11c
dtr
 targets certain macrophage 
subsets in peripheral organs 
274,276,277
. Indeed, we observed a loss of bone marrow macrophages 
after 6 days treatment of DT (Fig. 4.2d).  Of note, after 1 day treatment of DT, cDCs but not 
macrophages in the bone marrow were depleted, raising the possibility that macrophage loss is 
secondary to cDC loss (Fig. 4.2d).  
      Recent studies have identified Zbtb46 as a transcription factor that is expressed in cDCs but 
not in pDCs, macrophages or other myeloid or lymphoid cells
278,279
.   To confirm the specificity 
of Zbtb46 expression in cDCs, we analyzed Zbtb46
gfp
 mice, in which GFP is knocked into the 
Zbtb46 locus
279
.  As expected, Zbtb46-GFP was expressed at high levels in BM cDCs, but in 
neither bone marrow macrophages nor monocytes (Fig. 4.2e).   Since endothelial cells also 
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express Zbtb46
278,279
, we transplanted Zbtb46
dtr
 bone marrow into irradiated wild-type recipients 
to restrict Zbtb46
dtr
 to the hematopoietic lineage, thus to assess the effect of BM cDC ablation on 
HSPCs.  DT treatment on Zbtb46
dtr
 bone marrow chimeras resulted in a marked loss of BM 
cDCs (Fig. 4.2f).  Similar to CD11c
dtr
 bone marrow chimeras, we also observed a loss of bone 
marrow macrophages in the same mice following DT treatment, which occurred later than BM 
cDC ablation (Fig. 4.2f).  To determine whether this loss of macrophages was cell-autonomous, 
we generated mixed wild-type and Zbtb46
dtr
 bone marrow chimeras using similar transplantation 
method.  As expected, DT treatment resulted in the loss of Zbtb46
dtr
 derived but not wild-type 
derived BM cDCs (Fig. 4.2g).  In contrast, DT treatment resulted in decreases of both wild-type 
and Zbtb46
dtr
 derived bone marrow macrophages (Fig. 4.2h).  Collectively, these data strongly 
suggest that BM cDC ablation results in a secondary and non-cell autonomous loss of bone 
marrow macrophages.  
      Ablation of bone marrow macrophages has been reported to alter the HSPC niche and induce 
HSPC mobilization
7,52
.  Therefore, to precisely assess the role of BM cDCs on HSPC regulation 
and maintenance, it was necessary to include additional macrophage ablation model and double 
ablation model for comparison with BM cDC ablation model.  Recent studies have reported 
CD169
dtr
 may ablate bone marrow macrophages specifically
7,53,268,269
.  Thus, we transplanted 
Zbtb46
dtr
, CD169
dtr
, or CD169
dtr
: Zbtb46
dtr
 bone marrow into irradiated wild-type recipients.  6 
days of DT treatment on all three bone marrow chimeras did not induce any significant changes 
in bone marrow and spleen cellularity (Supplemental Fig. 4.1d,e).  In the bone marrow, all three 
chimeras showed no significant differences of KSL cells or CD150
+
 CD48
-
 KSL (KSL-SLAM) 
marked HSCs (Fig. 4.2i, supplemental Fig. 4.1f), although mild increases of CFU-C were 
observed (Fig. 4.2l).  Ablation of bone marrow macrophages in CD169
dtr 
bone marrow chimeras 
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resulted in weak mobilization of KSL cells and CFU-C into spleen and blood, but there was little 
mobilization of KSL-SLAM cells into spleen (Fig. 4.2j,m).  In contrast, ablation of BM cDCs in 
both Zbtb46
dtr
 and CD169
dtr
: Zbtb46
dtr
 bone marrow chimeras resulted in stronger mobilizations 
of KSL cells, KSL-SLAM cells and CFU-C into spleen and blood (Fig. 4.2j,k,m,n).  
Interestingly, there were no significant differences of HSPC mobilizations between Zbtb46
dtr
 and 
CD169
dtr
: Zbtb46
dtr
 bone marrow chimeras (Fig. 4.2j,k,m,n).  Overall, these data demonstrate 
that ablation of bone marrow macrophages only induces weak HSPC mobilization in bone 
marrow chimeras, and ablation of BM cDCs may induce stronger HSPC mobilization through 
both macrophage dependent and independent pathways. 
 
4.3.3. BM cDC ablation affects bone marrow vascular endothelial cells 
        Given BM cDCs are enriched in the perivascular region, we next assessed bone marrow 
vascular permeability after BM cDC ablation, as it has been reported to positively affect cell 
mobilization in bone marrow
280,281
.  BSA-FITC was injected into Zbtb46
dtr
 bone marrow 
chimeras treated with PBS, 1 day of DT, or 6 days of DT.  Mice were harvested 15 minutes later 
and immunofluorescent (IF) staining was performed on femurs to quantify BSA-FITC for 
estimating bone marrow vascular permeability (Fig. 4.3a)
282
.  We observed a trend of increasing 
vascular permeability along BM cDC ablation (Fig. 4.3c).  In addition, we quantified the 
percentage of vascular endothelial cells (VECs) in whole bone marrow in the same Zbtb46
dtr
 
bone marrow chimeras by IF staining and found the percentage of VECs increased after BM 
cDC ablation (Fig. 4.3b,d). Flow cytometry further confirmed that the number of bone marrow 
VECs increased 1 day after BM cDC ablation (Fig. 4.3e).  Collectively, these data show that 
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ablation of BM cDCs may result in potential activation of bone marrow VECs for increased 
vascular permeability and angiogenesis. 
 
4.3.4. BM cDC ablation activates sinusoidal endothelial cells and sinusoidal CXCR2 
signaling 
        To determine potential molecular pathways involved in BM cDC ablation induced 
activation of bone marrow VECs, we performed gene expression analysis in endothelial cells 
from Zbtb46
dtr 
bone marrow chimeras treated with 1 day of DT or PBS.  At this time point, only 
BM cDCs were ablated, but not bone marrow macrophages, thus the result would be specific to 
BM cDC ablation.  Sinusoidal endothelial cells (SECs) were marked as Lin
-
 CD31
+
 Sca1
-
 cells 
and arteriolar endothelial cells (AECs) were marked as Lin
-
 CD31
+
 Sca1
+
 cells, and both 
populations were sorted using FACS. We performed RNA microarray analysis on both 
populations, and PCA was performed to measure and visualize differences for each population 
before or after BM cDC ablation.  While AECs showed no significant differences between the 
two conditions, SECs may be activated after BM cDC ablation for differential gene expressions 
(Supplemental Fig. 4.2a,b).  To further test this possibility, we performed RNA sequencing 
analysis in SECs from Zbtb46
dtr
 bone marrow chimeras treated with 1 day of DT or PBS.  We 
performed t-distributed stochastic neighbor embedding (t-SNE) to measure and visualize 
differences between the two conditions and the result was consistent with the microarray analysis 
(Fig. 4.4a).  SECs were activated after BM cDC ablation and there were 635 significantly 
differentially expressed genes with >5 fold differences, p-value < 0.05 and FDR < 0.02.  To 
search for potential pathways activated in SECs after BM cDC ablation, gene set enrichment 
analysis (GSEA) was performed.  The most enriched gene set showed activation of chemokines 
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and cytokines related pathways (Fig. 4.4b).  Also, gene set for angiogenesis was highly enriched, 
which was consistent with the observed expansion of VECs measured by IF staining and flow 
cytometry (Fig. 4.3d,e and Fig. 4.4c).  Among expressed chemokine receptors in SECs, CXCR2 
was most highly up-regulated after BM cDC ablation (Fig. 4.4d). Importantly, recent and early 
studies have reported CXCR2 activation could induce vascular permeability and HSPC 
mobilization
72,283-285
.  We performed quantitative real-time PCR (qRT-PCR) on whole bone 
marrow RNAs from Zbtb46
dtr
 bone marrow chimeras treated with PBS, 1 day or 6 days of DT.  
Both ligands for CXCR2, CXCL1 (KC) and CXCL2 (Gro-β) were up-regulated following BM 
cDC ablation (Fig. 4.4e,f).  To confirm that this observation was not due to a non-specific up-
regulation of chemokines induced by acute inflammation, we measured whole bone marrow 
RNA level of CXCL12, a common and pro-inflammatory chemokine in the bone marrow, and 
found no increase after BM cDC ablation (Supplemental Fig. 4.2c). To further test whether there 
was an acute inflammation, we measured neutrophil numbers in blood and bone marrow
286,287
, 
and found little or no increase (Supplemental Fig. 4.2d,e). Both results suggested up-regulations 
of CXCL1 and CXCL2 were specific to BM cDC ablation. Thus, CXCR2 is activated in SECs 
after BM cDC ablation, which may play an important role for regulating sinusoidal vascular 
permeability and HSPC mobilization. 
 
4.3.5. CXCR2 signaling pathway is important for BM cDC ablation induced HSPC 
mobilization 
        To test our hypothesis on the role of CXCR2, we first confirmed prior studies
11-13, 32
 by 
testing whether activation of CXCR2 may induce vascular permeability using in vitro migration 
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assay. Human umbilical vein endothelial cells (HUVECs) were plated in the upper chamber of 
the Boyden chamber for migration assay to form a HUVEC layer, and treated with PBS or 
recombinant CXCL1 (rCXCL1) to activate CXCR2 signaling (Fig. 4.5a).  To test vascular 
permeability of the HUVEC layer for large molecules, Evan’s blue was added to the upper 
chamber of the Boyden chamber with 0.4μm pores in the membrane (Fig. 4.5a).  Quantified by 
light absorbance, the amount of Evan’s blue in the bottom chamber after 1 hour increased 
modestly upon CXCR2 activation, suggesting an increased permeability of the HUVEC layer 
(Fig. 4.5b).  To test the effects of CXCR2 activation on HSPC migration, CD34
+
 cells were 
isolated from healthy human bone marrow and added to the upper chamber of the Boyden 
chamber with 3μm pores in the membrane, and medium containing recombinant CXCL12 was 
added to the bottom chamber to induce cell migration
288-290
 (Fig. 4.5a).  A modest increase of 
cell migration through the HUVEC layer was observed after 24 hours upon CXCR2 activation 
(Fig. 4.5c).  To test the role of CXCR2 signaling on BM cDC ablation induced HSPC 
mobilization, we transplanted Zbtb46
dtr
 bone marrow into irradiated Cxcr2
-/-
 recipients, 
restricting knock-out of CXCR2 to the stromal cells and endothelial cells in the bone marrow of 
these recipients.  We then compared them with previous Zbtb46
dtr
 bone marrow chimeras in 
wild-type recipients, for HSPC mobilization after 6 days treatment of PBS or DT (Fig. 4.5d).  
BM cDC ablation did not affect bone marrow and spleen cellularity in Zbtb46
dtr
 Cxcr2
-/-
 bone 
marrow chimeras, and there was a mild decrease of cellularity compared to Zbtb46
dtr
 wild-type 
bone marrow chimeras with the same treatment (Supplemental Fig. 4.3a,b).  In the bone marrow 
of Zbtb46
dtr
 Cxcr2
-/-
 bone marrow chimeras, BM cDC ablation did not induce any significant 
differences in KSL cells (Fig. 4.3e) and KSL-SLAM cells (Supplemental Fig. 4.3c), although 
there might be a trend of mild increase of CFU-C which was similar to the pattern observed in 
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Zbtb46
dtr
 wild-type bone marrow chimeras (Supplemental Fig. 4.3d).  In the spleen of Zbtb46
dtr
 
Cxcr2
-/-
 bone marrow chimeras, BM cDC ablation resulted in weaker mobilizations of KSL cells, 
KSL-SLAM cells and CFU-C, compared to Zbtb46
dtr
 wild-type bone marrow chimeras (Fig. 
4.5f-h).  Similar to the spleen, a weaker mobilization of CFU-C was observed in the blood of 
Zbtb46
dtr
 Cxcr2
-/-
 bone marrow chimeras, compared to Zbtb46
dtr
 wild-type bone marrow 
chimeras (Fig. 4.5i).  Collectively, data from both in vitro and in vivo experiments support our 
hypothesis that CXCR2 signaling plays an important role in the regulation of HSPC mobilization 
induced after BM cDC ablation. 
 
4.4. Summary 
        In conclusion, data from this study suggests BM cDC as a novel perivascular niche 
component that regulates HSPC retention and trafficking, at least in part, through its regulation 
of sinusoidal CXCR2 signaling and vascular permeability.  This observation is consistent with 
the findings from our colleagues, where Dr. John Dipersio’s group shows endothelial CXCR2 is 
important for Gro-β induced neutrophil mobilization into the blood.  Our results do not provide 
evidence to explain how BM cDCs regulate SECs.  However, as bone marrow macrophage has 
been reported to regulate HSPCs through indirect regulation of stromal cells
7,52
, we suspect 
similar process may be involved.   
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4.7. Figures 
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Figure 4.1. Classical dendritic cells (cDCs) are enriched in the perivascular region and may 
be functionally specific for the perivascular niche. (a) Representative flow plots showing the 
gating strategy used to identify bone marrow monocytes, macrophages, and cDCs in Cx3cr1
gfp/+
 
mice. Gr-1
hi
 neutrophils and B220
+
/CD19
+
 B cells were excluded as shown in the left panel. 
Monocytes were identified as CX3CR1-GFP
+
 MHC II
low
 cells, cDCs as CX3CR1-GFP
high
 
MHCII
high
 cells, and macrophages as CX3CR1-GFP
low
 MHCII
+
 B220
-
 cells. (b) The gated 
monocyte, macrophage, and cDC populations were profiled for expression of the indicated 
lineage markers. FMO, fluorescence minus one control. (c) Representative photomicrographs of 
femur sections from Cx3Cr1
gfp/+
 mice. Slides were stained with GFP (green) (i), MHC II (red) 
(ii) and the merge (iii). Slides were stained with GFP (green) (iv), Sca1
+
 arterioles (red) (v), VE-
Cadherin
+
 venous sinusoids and arterioles (white) (vi) and merge (vii); higher magnification of 
boxed region (viii). Yellow arrows indicate cDCs. Counterstaining with DAPI highlights nuclei 
(blue). (d,e) Quantification of the distance from cDCs to the nearest venous sinusoid (d) or 
arteriole (e) (data pooled from n = 3 mice).  (f) Representative flow plot showing the expression 
of two murine cDC markers, XCR1 for cDC1 and CD11b for cDC2, in murine bone marrow 
cDCs, gated as Gr-1
-
 B220
-
 MHCII
high
 CD11c
high
 cells. (g) Representative flow plot showing the 
expression of two human cDC markers, CD141 for cDC1 and CD1c for cDC2, in human bone 
marrow cDCs, gated as Lin
-
 CD14
-
 CD13
+
 CD33
+
 CD11c
+
 HLA-DR
+
 cells. (h) A heat map 
comparing the expressions of all chemokines and their receptors between mouse BM cDCs and 
mouse spleen (Sp) cDC2s (GSE110789, Durai V. 2018).  Data represent mean ± SEM. 
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Figure 4.2. BM cDC ablation induces a loss of macrophage and HSPC mobilization. (a-d) 
Bone marrow from CD11c
dtr
 mice were transplanted into irradiated wildtype recipients and after 
eight weeks, the resulting chimeras were treated with PBS or DT for 6 days. The number of 
CFU-C in bone marrow (a), spleen (b) and blood (c) were quantified (n = 10 mice per cohert). 
(d) CD11c
dtr
 bone marrow chimeras were treated with DT for 1 day (n = 3 mice), 6 days (n = 10 
mice), or with PBS (n = 10 mice), and BM cDCs and macrophages were quantified by flow 
cytometry. (e) Bone marrow monocytes (Gr-1
low
 B220
-
 CD115
+
 cells), macrophages (B220
-
 
MHCII
+
 F4/80
+
 cells), and cDCs (MHCII
high
 CD11c
high
 cells) from Zbtb46
gfp/+
 mice were 
assessed for Zbtb46-GFP expression. FMO means fluorescence minus one control. (f) Zbtb46
dtr
 
bone marrow chimeras were generated using same method and were treated with DT for 1 day (n 
= 5 mice), 2 days (n = 5 mice), 6 days (n=12 mice) or with PBS (n = 11mice) and BM cDCs and 
macrophages were quantified. (g,h) Bone marrow from wild-type (Ly5.1) and Zbtb46
dtr 
(Ly5.2) 
mice were mixed (1:1) and transplanted into irradiated wild-type recipients (Ly5.1/5.2). The 
resulting wild-type and Zbtb46
dtr
 mixed bone marrow chimeras were treated with PBS or DT for 
6 days, and the number of cDCs (g) and macrophages (h) in the bone marrow that were derived 
from wild-type (WT) or Zbtb46
dtr
 (Zbtb46-DTR) cells were quantified (n = 5 mice per cohort).  
(i-n) Zbtb46
dtr
 (Zbtb46-DTR), CD169
dtr 
(CD169-DTR) and CD169
 dtr
:Zbtb46
dtr
 (CD169/Zbtb46-
DTR) bone marrow were transplanted into wild-type recipients. Eight weeks after 
transplantation, these mice were treated with PBS or DT for 6 days. The numbers of Lineage
-
 
(CD45, CD31, Ter119, Gr-1) Sca1
+
 C-kit
+
 (KSL) cells in bone marrow (i) and spleen (j), the 
number of CD150
+
 CD48
-
 KSL (KSL-SLAM) cells in spleen (k), and the numbers of CFU-C in 
bone marrow (l), spleen (m) and blood (n) were quantified (n = 8-18 mice per cohort). Data 
represent the mean ± SEM.  *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 compared 
with PBS-treated or day 0 mice if no top line indicating the specific comparison groups. “n.s.” 
means no significance.  
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Figure 4.3. Ablation of BM cDCs affects bone marrow vascular endothelial cells (VECs). 
(a,b) Representative photomicrographs of femur sections from Zbtb46
dtr
 bone marrow chimeras 
treated with PBS (left), 1 day of DT (1D-DT, middle) or 6 days of DT (6D-DT, right). (a) BSA-
FTIC was injected into these mice 15mins before sacrifice, and was labeled in green. Slides were 
stained for VE-Cadherin
+
 /CD31
+
 VECs (red). (b) Slides were stained for VE-Cadherin
+
 /CD31
+
 
VECs (red). Counterstaining with DAPI highlights nuclei (blue). Original magnification, 200X. 
(c) Vascular permeability in bone marrow for BSA-FITC was measured and normalized to PBS 
treated group. (d) Percentage of VEC volumes in the bone marrow of these mice were quantified 
(n = 9, 8, 7 mice for PBS, 1D-DT and 6D-DT groups). (e) Bone marrow VECs in Zbtb46
dtr
 bone 
marrow chimeras treated with PBS or 1D-DT were quantified by flow cytometry, gated as 
Lineage
-
 (CD45, Ter119, Gr-1) CD31
+
 cells (n = 4 or 6 mice for PBS or 1D-DT groups). Data 
represent the mean ± SEM.  *P < 0.05; **P < 0.01compared with PBS-treated mice. 
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Figure 4.4. Ablation of BM cDCs activates sinusoidal endothelial cells and sinusoidal 
CXCR2 signaling. (a) Sinusoidal endothelial cells were sorted from Zbtb46
dtr
 bone marrow 
chimeras treated with PBS or 1D-DT, and RNA-sequencing (RNA-seq) analysis was performed 
in these cells. We performed t-distributed stochastic neighbor embedding (t-SNE) test to measure 
and visualize differences between PBS (n = 4 mice) and 1D-DT (n = 3 mice) groups. (b,c) RNA-
seq data were analyzed using gene set enrichment analysis (GSEA) and two significantly 
enriched gene sets of interest were shown. (d) Expression levels of all expressed chemokine in 
sinusoidal endothelial cells. (e) CXCL1 and (f) CXCL2 expressions were analyzed by 
quantitative real-time PCR (qRT-PCR) in whole bone marrow from Zbtb46
dtr
 bone marrow 
chimeras treated with PBS, 1D-DT or 6D-DT (n = 6, 5, 5 mice for these groups).  Data represent 
the mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001compared with PBS-treated mice. 
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Figure 4.5. CXCR2 signaling pathway is important for BM cDC ablation induced HSPC 
mobilization. (a-c) Human umbilical vein endothelial cells (HUVECs) were cultured in 
endothelial cell (EC) medium in the upper chamber of the Boyden Chamber for migration assay. 
HUVECs were treated with PBS or recombinant CXCL1, incubated at 37ºC, 5% CO2.  (b) 
Evan’s blue was added to the upper chamber with Hank’s balanced salt saline (HBSS) in the 
bottom chamber, polycarbonate membrane pore size = 0.4µm.  After 1 hour incubation, the 
amount of Evan’s blue in the bottom chamber was quantified by measuring light absorbance (n = 
5 or 6 per group).  (c) CD34
+
 human bone marrow cells from healthy donor were added to the 
upper chamber, with EC medium containing 100ng/mL SDF1in the bottom chamber, 
polycarbonate membrane pore size = 3µm.  After 24 hours incubation, the number of migrated 
CD34
+
 cells in the bottom chamber was quantified by cellometer (n = 11 or 12 per group).  (d) 
Bone marrow cells from Zbtb46
dtr
 mice were transplanted into irradiated wild-type (previously 
done in Fig 2) or Cxcr2
-/-
 recipients.  Eight weeks after transplantation, mice were treated with 
PBS or DT for 6 days.  (e-i) The number of KSL cells in bone marrow (e) and spleen (f), the 
number of KSL-SLAM cells in spleen (g), and the number of CFU-C in spleen (h) and blood (i) 
were quantified (n = 12, 16, 6, 6 mice for WT PBS, WT DT, Cxcr2
-/-
 PBS and Cxcr2
-/-
 DT 
groups).  Data represent the mean ± SEM.  *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 
comparing to PBS-treated group if no top line indicating the specific comparing groups. 
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4.8. Supplemental Figures 
 
Supplemental Figure 4.1. BM cDC ablation induces a loss of macrophage and HSPC 
mobilization. (a) Bone marrow from CD11c
dtr
 mice were transplanted into irradiated wild-type 
recipients and after eight weeks, the resulting chimeras were treated with PBS or DT for 6 days. 
(b,c) KSL cells were quantified in bone marrow (b) and spleen (c) (n = 8-10 mice per cohert). 
(d-f) Zbtb46
dtr
 (Zbtb46-DTR), CD169
dtr 
(CD169-DTR) and CD169
 dtr
:Zbtb46
dtr
 (CD169/Zbtb46-
DTR) bone marrow were transplanted into wild-type recipients. Eight weeks after 
transplantation, mice were treated with PBS or DT for 6 days.  Total cellularity in bone marrow 
(d) and spleen (e), and KSL-SLAM cells (f) in bone marrow were quantified (n = 10-18 mice per 
cohort). Data represent the mean ± SEM.  *P < 0.05; **P < 0.01 compared with PBS-treated 
mice. 
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Supplemental Figure 4.2. Ablation of BM cDCs activated sinusoidal endothelial cells and 
sinusoidal CXCR2 signaling. (a,b) Arteriolar and sinusoidal endothelial cells (AECs and SECs) 
were sorted from Zbtb46
dtr
 bone marrow chimeras treated with PBS or 1 day of DT (1D-DT), 
and RNA microarray analyses were performed in these populations.  We performed principal 
component analysis (PCA) to measure and visualize differences between PBS and 1D-DT 
groups, for (a) AECs (n = 4 or 5 mice for PBS or 1D-DT groups) and (b) SECs (n = 2 or 3 mice 
for PBS or 1D-DT groups).  (c) CXCL12 expression was measured by quantitative real-time 
PCR (qRT-PCR) in whole bone marrow from Zbtb46
dtr
 bone marrow chimeras treated with PBS, 
1D-DT or 6D-DT (n = 6, 5, 5 mice for these groups). (d,e) Zbtb46
dtr
 bone marrow chimeras were 
treated with PBS or 1 day of DT, neutrophils were quantified in blood by Hemavet Hematology 
Analyzer (n = 11 or 4 for each group) (d) and in bone marrow by flow cytometry, gated as Gr-
1
high
 cells (n = 11 mice per group) (e).  Data represent the mean ± SEM  *P < 0.05 compared 
with PBS-treated mice. 
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Supplemental Figure 4.3. CXCR2 signaling pathway is important for BM cDC ablation 
induced HSPC mobilization. (a-d) Bone marrow cells from Zbtb46
dtr
 mice were transplanted 
into irradiated wild-type (previously done in Fig 2) or Cxcr2
-/-
 recipients.  Eight weeks after 
transplantation, mice were treated with PBS or DT for 6 days. Total cellularity in bone marrow 
(a) and spleen (b), KSL-SLAM cells (c) and CFU-C (d) in bone marrow were quantified (n = 6-
17 mice per cohort). Data represent the mean ± SEM.  *P < 0.05. 
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS 
 
        The goal of this work is to improve the overall understanding of the bone marrow 
perivascular niche. Here, we further characterized a known bone marrow niche component, 
mesenchymal stromal cells, and proposed a novel niche cell component, bone marrow classical 
dendritic cells (BM cDCs). In Chapter 2, we examined the heterogeneity of mesenchymal 
stromal cells using different transgenic Cre models and identified a subset of CAR cells 
potentially enriched for osteoprogenitors. This study further highlights the heterogeneity of 
mesenchymal stromal cells in the bone marrow and suggests appropriate models to interrogate 
this heterogeneity. In Chapter 3, we used a Cxcl12 conditional deletion model and multiple 
stromal specific transgenic Cre models to assess the role of CXCL12 from different stromal cell 
populations on the regulation of B lymphopoiesis. We show that CXCL12 from Ocn-Cre 
targeted stromal cells is important in the regulation of mature naive B cells and memory B cells 
in the bone marrow. This study demonstrates the functional heterogeneity of stromal cells and 
may provide insights to the development of potential therapies for B cell related diseases. In 
Chapter 4, we used ablation models to assess the role of BM cDCs in the regulation of HSPCs in 
the bone marrow and discovered that BM cDCs serve as an important hematopoietic niche 
component to regulate HSPC trafficking through its regulation of sinusoidal CXCR2 signaling. 
These data improve our understanding of the hematopoietic niche and provide potential targets 
for the development of cell mobilization related treatment.  
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5.1. Targeting mesenchymal stromal cells with different Cre-recombinase transgenes 
5.1.1. Summary 
        In Chapter 2, we characterized three Cre-recombinase transgenes for their targeting 
specificity on bone marrow stromal cells. Ocn-Cre has been widely used to target osteoblasts in 
past studies
245,247,248
. Our data show that Ocn-Cre targets not only all osteoblasts, but also 
osteocytes, ~70% of CAR cells, and the majority of arteriolar pericytes. Dmp1-Cre has been 
widely used to target osteocytes 
250,252,266
.  We show that Dmp1-Cre targets all osteoblasts, as 
well as ~30% of CAR cells. Expression profiling of these CAR cells shows higher expression of 
genes associated with mature osteoblasts, suggesting their potential enrichment for 
osteoprogenitors. We also, for the first time, characterized the bone marrow stromal cells 
targeted by a Tagln-Cre transgene, and show that Tagln-Cre targets all osteoblasts, ~70% of 
CAR cells, and both venous sinusoidal and arteriolar pericytes. Collectively, we have rigorously 
defined the targeting specificities in the bone marrow for the three Cre-recombinase transgenes. 
Ocn-Cre and Dmp1-Cre target broader stromal cell populations than previously appreciated, 
which should be considered when designing future studies. Moreover, we present Tagln-Cre as a 
new tool to efficiently target both venous sinusoidal and arteriolar pericytes in the bone marrow.  
 
5.1.2. Are Dmp1-Cre targeted stromal cells truly enriched for osteoprogenitors? 
        Our data suggests that Dmp1-Cre targeted stromal cells may be enriched for 
osteoprogenitors. However, this hypothesis is only based on gene expression profiling using 
RNA microarray and further experiments are required to confirm this finding. First, quantitative 
real-time PCR may be used to confirm the up-regulation of genes associated with mature 
osteoblasts, which were detected by RNA microarray. Second, we may perform functional 
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assays to test the osteoprogenic capacity of Dmp1-Cre targeted stromal cells. We may sort these 
cells using the same strategy as for gene expression profiling, and culture the sorted cells in vitro 
to test their multi-lineage capacity using colony forming unit (CFU) assays for adipocytes (CFU-
A), osteoblasts (CFU-Ob) and chondrocytes (CFU-Ch). Total CAR cells and Ocn-Cre targeted 
CAR cells may also be sorted and cultured to test their multi-lineage capacity. By comparing 
their multi-lineage capacities, especially the capacity to form osteoblasts among these different 
subsets of CAR cells, we will be able to confirm whether Dmp1-Cre targeted stromal cells are 
truly enriched for osteoprogenitors.  
 
5.1.3. Further characterize the heterogeneity of CAR cells 
         Prior studies have discussed the heterogeneity of mesenchymal stromal cells in the bone 
marrow and have described different subsets of stromal cells for their specific functions, such as 
LepR
+
 cells and Nestin-GFP cells
10,12
. In this study, we further identified Dmp1-Cre targeted 
stromal cells to include potential osteoprogenitors. However, it remains unanswered how many 
functionally different subsets of stromal cells may exist. Recent studies suggest that distinct 
niches may exist to regulate different types of cells, such as quiescent or more proliferative 
HSCs
12,18,79
. Further dissecting the heterogeneity of stromal cells will provide insights to better 
characterize distinct niches with more specific functions. This will improve our understanding of 
the regulation of different cells in the bone marrow, providing fundamental knowledge to support 
future research in both basic and clinical science. For future studies, CAR cells, representing the 
majority of mesenchymal stromal cells, may be sorted from Cxcl12
gfp
 mice and analyzed by 
single cell RNA sequencing. Based on the gene expression profile, clustering analysis may be 
performed to discover more specific subsets of CAR cells. It is important to notice that due to the 
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overall similarity among CAR cells, clustering analysis may be inefficient to detect more specific 
cell subsets. Alternatively, differential gene expressions should also be analyzed and such 
analysis should focus on genes representing surface markers or genes with important functions in 
the regulation of the bone marrow niche.    
 
5.2. CXCL12 from Ocn-Cre targeted mesenchymal stromal cells regulates late-stage 
B cell development 
5.2.1. Summary 
        In Chapter 3, we assessed the role of CXCL12 from different stromal cells in the regulation 
of B cell development in the bone marrow. We show that CXCL12 from Ocn-Cre targeted 
stromal cells is specifically important for the homing and/or retention of mature naive B cells. 
We also show that Dmp1-Cre targeted stromal cells play no significant role in the regulation of B 
cell development, consistent with our prior study showing that Dmp1-Cre targeted CAR cells 
express low levels of IL-7
19
. In addition, our data suggests that CXCL12 from Ocn-Cre targeted 
stromal cells regulates memory B cells specifically in the bone marrow. Collectively, these data 
suggest that B cells require distinct niches at different stages of development, and Ocn-Cre 
targeted stromal cells may represent a specific niche for late-stage B cell development. 
Moreover, Ocn-Cre targeted stromal cells may also regulate memory B cells, thus potentially 
contributing to the regulation of B cell immune memory and humoral immunity. This study may 
provide insights to further understand immune memory, which in turn will contribute to 
improvements in the treatment of the relevant diseases.  
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5.2.2. Functionally characterize the role of bone marrow memory B cells in the regulation 
of humoral immunity 
        In this study, we used NP-CGG to induce NP-specific memory B cells and observed a 
significant reduction of these cells in the bone marrow of Ocn-Cre:Cxcl12
flox/flox
 mice compared 
to the Cxcl12
flox/flox
 control mice. Of notice, the number of memory B cells in the bone marrow 
constitutes ~40% of total memory B cells, including memory B cells from the spleen (Fig 
3.5A&B), assuming one femur represents ~9% of total bone marrow cells. We observed ~50% 
reduction in memory B cells in the bone marrow of Ocn-Cre:Cxcl12
flox/flox
 mice, roughly 
representing a 20% reduction in total memory B cells. It remains questionable whether this 
modest reduction of memory B cells has a significant impact on memory B cell derived humoral 
immunity. To test this, we have an ongoing study in which a similar number of bone marrow 
cells containing NP-specific memory B cells from Ocn-Cre:Cxcl12
flox/flox
  or Cxcl12
flox/flox
  mice 
will be transferred into IgHa/J mice, followed by secondary immunization with NP-CGG. 
ELISA will be performed to quantify the NP-specific IgG1b antibodies generated by NP-specific 
memory B cells from the donor mice.  In addition, using the same method, we could compare the 
function of NP-specific memory B cells from the bone marrow and the spleen.  
 
5.2.3. How does CXCL12 ablation in Ocn-Cre targeted stromal cells affect other cells in the 
bone marrow? 
        Our study focused on how CXCL12 ablation in different stromal cells regulates B cell 
development. However, our preliminary data also suggests a significant reduction of T cells, 
especially CD8
+
 T cells and Foxp3
+
 regulatory T (Treg) cells in the bone marrow upon CXCL12 
ablation in Ocn-Cre targeted stromal cells (Fig 5.1A). In contrast, no significant reduction of T 
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cells was observed in Dmp1-Cre:Cxcl12
flox/flox
 mice (Fig 5.1B). These data suggest that CD8
+
 T 
cells and Treg cells, as well as mature naive B cells and memory B cells, may share the same 
niche in the bone marrow. A recent study has suggested Foxp3
+
 regulatory T cells play an 
important role in the regulation of B lymphopoiesis
291
. Thus, it is possible that Treg cells may be 
important for the regulation of mature naive B cells and memory B cells in our CXCL12 ablation 
model. To test this possibility, the same CXCL12 ablation model may be applied in a 
background of Treg cell deficient mice. The effects of CXCL12 ablation in Ocn-Cre targeted 
stromal cells on mature naive B cells and memory B cells will be assessed in the lack of Treg 
cells. 
         Moreover, prior studies have suggested CD8
+
 T cells in the bone marrow may function as 
memory T cells
292
. Although this hypothesis needs further confirmation, it is important to note 
that two potential populations of memory B cells and memory T cells are both regulated by 
CXCL12 from Ocn-Cre targeted stromal cells. These data indicate that a unique bone marrow 
niche may exist to regulate memory cells, thus potentially regulating immune memory in the 
bone marrow. More interestingly, the fact that memory B cells and memory T cells may share 
the same niche suggests the potential necessity in our future research to focus on a whole system, 
instead of a specific cell type. This may provide a different perspective to investigators when 
considering and designing their future experiments.  
 
5.2.4. Do Ocn-Cre targeted stromal cells regulate mature naive B cells and memory B cells 
through other pathways? 
        CXCL12 is an important bone marrow niche factor regulating hematopoiesis and B 
lymphopoiesis
20
. Our prior study has suggested the critical role of CXCL12 in the regulation of 
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B cell development at different stages
3
. In this study, we show that CXCL12 from Ocn-Cre 
targeted stromal cells regulates mature naive B cells and memory B cells, suggesting these cells 
are potentially an important component for a specific B cell niche. As previously discussed, B 
cell development is a complicated process requiring the contribution from different molecular 
pathways. To better understand the role of Ocn-Cre targeted stromal cells in the regulation of B 
lymphopoiesis, it is necessary to further characterize these cells to test whether additional 
pathways are involved in their regulation of B cells.  
        To assess this possibility, we are currently breeding Ocn-Cre:ROSA26
Ai9/+
:Col2.3
gfp
 and 
Dmp1-Cre:ROSA26
Ai9/+
:Col2.3
gfp
 mice. The ROSA26
Ai9/+
 transgene allows for the identification 
of Ocn-Cre or Dmp1-Cre targeted cells as tdTomato
+
 cells
19
.  The Col2.3
gfp
 transgene allows for 
the identification of osteoblasts and osteoblast progenitors as GFP
+
 cells
293
. In combination, we 
can accurately sort Ocn-Cre or Dmp1-Cre targeted tdTomato
+
 GFP
-
 stromal cells, excluding 
osteoblasts. We will then perform RNA sequencing analysis on these two subsets of stromal cells 
and compare their gene expression profiles. We will try to discover genes enriched in Ocn-Cre 
targeted stromal cells that are potentially important for the regulation of B cells, especially 
mature naive B cells and memory B cells. Among these genes, we will select candidates for 
further functional tests, potentially using transgenic ablation models depending on their 
availability. This future study may help improve our understanding of the heterogeneity of 
stromal cells and the regulation of B cell development by specific stromal cells.  
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5.3. Bone marrow cDCs regulate hematopoietic stem and progenitor cell trafficking  
5.3.1. Summary 
        In Chapter 4, we assessed the role of bone marrow (BM) cDCs in the regulation of the 
hematopoietic niche and HSPCs. Using Cx3cr1
gfp
 mice, we identified cDCs in the bone marrow 
and show that they localize to both sinusoidal and arteriolar regions. We further discovered that 
the majority of these BM cDCs have a cDC2-like immunophenotype, but their gene expression 
profile suggests that they are functionally different from conventional cDC2s in the spleen. 
Interestingly, we also identified a similar population of BM cDCs in human bone marrow, 
emphasizing the potential clinical relevance of this study. Using ablation models, we show that 
the ablation of BM cDCs results in a secondary, non-cell autonomous loss of BM macrophages, 
which have been previously reported to regulate HSPCs
7
.  In addition, we show that the ablation 
of BM cDCs induces HPSC mobilization, at least in part, through a macrophage independent 
mechanism. Since HSPC mobilization is often associated with changes in the perivascular niche, 
we characterized endothelial cells and discovered endothelial expansion following BM cDC 
ablation. We also revealed a robust up-regulation of CXCR2 in sinusoidal endothelial cells and 
the up-regulation of two major ligands of CXCR2 in the bone marrow, CXCL1 and CXCL2. 
CXCR2 activation has been reported to induce vascular permeability and HSPC mobilization
72
, 
thus we assessed the role of CXCR2 in the regulation of HPSC mobilization following BM cDC 
ablation. We show that activation of CXCR2 in vitro induces vascular permeability and HSPC 
migration. Moreover, we show that deletion of CXCR2 in non-hematopoietic cells significantly 
attenuates HSPC mobilization after BM cDC ablation. Collectively, these data suggest that BM 
cDCs play an important role in regulating HSPC trafficking, at least in part, through its 
regulation of sinusoidal CXCR2 signaling and vascular permeability.  
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5.3.2. Further assess the role of CXCR2 in endothelial cells 
        To examine the role of CXCR2 in the regulation of HSPC mobilization following BM cDC 
ablation, we transplanted Zbtb46
dtr
 bone marrow into irradiated Cxcr2
-/-
 mice. The deletion of 
CXCR2 is only restricted to non-hematopoietic cells in the bone marrow, including both 
endothelial cells and stromal cells. It is possible that the attenuated HSPC mobilization following 
BM cDC ablation may be a result of CXCR2 deletion in bone marrow stromal cells. To rule out 
this possibility, we have an ongoing experiment using VEcad-Cre:Cxcr2
flox/flox
 mice as the 
recipients for Zbtb46
dtr
 bone marrow transplant. This will allow us to restrict the deletion of 
Cxcr2 to endothelial cells, excluding bone marrow stromal cells. We will then perform flow 
cytometry and CFU-C tests to assess HSPC mobilization after BM cDC ablation in these VEcad-
Cre:Cxcr2
flox/flox
 mice.  
 
5.3.3. How do BM cDCs regulate sinusoidal endothelial cells? 
        We have discovered that BM cDCs may regulate HSPC trafficking through its regulation of 
sinusoidal CXCR2 signaling. However, how BM cDCs regulate sinusoidal endothelial cells 
remains unknown. A prior study on BM macrophages suggests that they regulate HPSC 
trafficking through mesenchymal stromal cells
7
. BM cDCs and BM macrophages share the same 
myeloid origin, so we hypothesize that BM cDCs may also regulate mesenchymal stromal cells. 
To test this hypothesis, we performed a pilot experiment in which bone marrow stromal cells 
(BMSCs) were sorted from Zbtb46
dtr
 bone marrow chimeras treated with 1 day of DT or PBS. 
RNA microarray analysis on these cells suggested a potential functional change in BMSCs 
following BM cDC ablation (Fig. 5.2A). Expression of CXCL1 and CXCL2 were up-regulated 
in the whole bone marrow following BM cDC ablation to activate sinusoidal CXCR2 signaling 
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(Fig. 4.4E&F). Surprisingly, the expression of CXCL1, but not CXCL2, was significantly 
increased in BMSCs by more than 3-fold following BM cDC ablation (Fig. 5.2B&C), indicating 
the partial involvement of BMSCs in the regulation of sinusoidal CXCR2 signaling. Collectively, 
these preliminary data suggest that BM cDCs may regulate sinusoidal endothelial cells, at least 
in part, through their regulation of BMSCs. 
        While BMSCs may regulate sinusoidal endothelial cells through their up-regulation of 
CXCL1, it remains unknown how BM cDCs regulate BMSCs. Since the majority of BM cDCs 
and BMSCs are both localized to the perivascular region, it is likely that the two cell populations 
are in close proximity. Thus, it is possible that BM cDCs may directly regulate BMSCs through 
the release of intermediate molecules or direct physical interaction. To test this possibility, gene 
expression profiles from both cell populations will be compared to identify potential factor/ 
receptor pairs expressed by BM cDCs and BMSCs, respectively. In addition, 
Zbtb46
gfp
:Cxcl1
DsRed
 mice may be generated, in which BM cDCs are marked as GFP
+
 cells and 
BMSCs are marked as DsRed
+
 cells. Bone sections from these mice may then be imaged to 
check whether direct physical interaction exists between BM cDCs and BMSCs. In summary, 
understanding the mechanisms involved in the regulation of BMSCs and sinusoidal endothelial 
cells by BM cDCs will provide insights to the advancement in both basic and clinical research. 
 
5.3.4. How do BM cDCs regulate BM macrophages? 
        In Zbtb46
dtr
 bone marrow chimeras, the ablation of BM cDCs was observed 1 day after DT 
treatment, and the ablation of BM macrophages was observed at day 2. Our data suggests that 
BM cDC ablation may induce a secondary, non-cell autonomous loss of BM macrophages. 
However, the mechanism involved in this regulation remains unclear. One possibility is that the 
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death of BM cDCs will release signaling molecules, such as chemokines and cytokines, which 
may induce cell death specifically in BM macrophages. Another possibility is that BM cDCs 
may provide critical signals to support the survival of BM macrophages through their release of 
survival factors or through direct physical interaction. To test these possibilities, gene expression 
profiles from both BM cDCs and BM macrophages will be compared to identify potential 
signaling pathways contributing to the survival or cell death of BM macrophages. In contrast to 
direct regulation, BM cDCs may regulate BM macrophages indirectly through intermediate cells, 
such as BMSCs. In addition to the above scenarios, BM cDCs and BM macrophages share the 
same myeloid origin, thus the loss of BM cDCs may affect their common progenitor to undergo 
a more cDC lineage committed differentiation, preventing the replenishment of BM 
macrophages. Future research may include characterization of myeloid progenitors, BMSCs and 
other cell populations in the bone marrow, before or after BM cDC ablation. Better 
understanding of the mechanisms involved in the secondary loss of BM macrophages will likely 
provide targets to the development of macrophage-depleting agents with significant clinical 
applicability.    
 
5.3.5. Assess the effects of BM cDC ablation on osteoblasts 
        Other than sinusoidal endothelial cells, we also assessed the effects of BM cDC ablation on 
osteoblasts. Zbtb46
dtr
 bone marrow chimeras were treated with DT for 6 days and we observed a 
significant decrease in osteocalcin (Bglap2) mRNA level in the whole bone marrow (Fig. 5.3A). 
Osteocalcin is mainly expressed by mature osteoblasts, thus our data suggests a suppression of 
osteoblasts following BM cDC ablation. To test the effects of BM cDC ablation on osteoblasts, 
Zbtb46
dtr
 bone marrow was transplanted into Col2.3
gfp
 mice in which osteoblasts are marked as 
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GFP
+
 cells, followed by DT or PBS treatment 8 weeks after transplant. Using flow cytometry, 
we quantified and sorted GFP
+
 osteoblasts from DT or PBS treated Zbtb46
dtr
 bone marrow 
chimeras. To our surprise, no significant difference was observed in the number of osteoblasts 
after BM cDC ablation, compared to the control group (Fig. 5.3B). In addition, we tested the 
expression of osteocalcin in sorted GFP
+
 osteoblasts and observed a significant decrease in the 
osteocalcin mRNA level after BM cDC ablation (Fig. 5.3C). Collectively, our preliminary data 
suggests that osteoblasts might be functionally suppressed following BM cDC ablation. 
        A prior study suggested that BM macrophage ablation might induce a functional 
suppression of osteoblasts
7
. To test whether BM cDCs may regulate osteoblasts in a 
macrophage-independent pathway, we compared bone marrow chimeras transplanted with 
Zbtb46
dtr
, CD169
dtr
 and CD169
dtr
:Zbtb46
dtr
 bone marrow for the ablation of BM cDCs, BM 
macrophages and both. The whole bone marrow osteocalcin mRNA levels in these mice suggest 
that BM cDCs may regulate osteoblasts in a macrophage-independent pathway (Fig. 5.3D). 
However, large variability exists in the osteocalcin mRNA level in CD169
dtr
 bone marrow 
chimeras, and further testing is necessary to support this hypothesis. One potential experiment is 
to transplant CD169
dtr
 bone marrow into Col2.3
gfp
 mice and treat these chimeras with 6 days of 
DT to ablate BM macrophages. We can then sort GFP
+
 osteoblasts and test their expression of 
osteocalcin. In addition, it is more important to figure out the mechanism involved in the 
regulation of osteoblasts by either BM cDCs or BM macrophages. These two populations mainly 
localize to the perivascular region and osteoblasts localize to the endosteal region, thus 
intermediate cells may be involved to relay the signals for their interactions. Further 
characterization of osteoblasts using RNA-seq analysis before and after BM cDC ablation may 
help detect potential pathways driving the suppression of osteoblasts. Potential factors activating 
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these pathways will then be tested in whole bone marrow or specific cell populations. 
Osteoblasts are a critical component for osteogenesis and understanding the suppression of 
osteoblasts will provide important insights to the development of potential therapies for bone 
related diseases.   
 
5.4. Conclusion 
        In this thesis, we further characterized the roles and functions of two bone marrow niche 
components. In Chapter 2, we show that Ocn-Cre, Dmp1-Cre and Tagln-Cre transgenes target 
different subsets of bone marrow mesenchymal stromal cells. We revealed that Ocn-Cre and 
Dmp1-Cre target broader cell populations than previously appreciated, which should be 
incorporated in the design of future study. We also suggest that Dmp1-Cre targeted stromal cells 
may be enriched for osteoprogenitors. In Chapter 3, we tested the function of CXCL12 from 
different subsets of stromal cells on B lymphopoiesis. We show that CXCL12 from Ocn-Cre 
targeted stromal cells is particularly important for the regulation of mature naive B cells and 
memory B cells, potentially through the regulation of their homing and/or retention. In Chapter 
4, we assessed the role of BM cDCs in the regulation of the HSPCs. We show that BM cDC 
ablation results in a secondary, non-cell autonomous loss of BM macrophages. We also 
discovered that BM cDCs may regulate HSPC trafficking in a macrophage independent pathway, 
at least in part, through its regulation of sinusoidal CXCR2 signaling and vascular permeability. 
Collectively, this thesis study helps improve our understanding of the heterogeneity of stromal 
cells and the regulation of B lymphopoiesis by different stromal cells. In addition, we propose a 
novel bone marrow niche component that regulates HSPC trafficking. Although future research 
is required to mechanistically study the stromal cells and BM cDCs, the results generated from 
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this study provide insights that are important for the advancement in both basic and clinical 
biology.   
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5.5. Figures 
 
Figure 5.1. CXCL12 expression in Ocn-Cre targeted stromal cells is important for the 
regulation of T cells. A&B. Femurs were harvested from Ocn-Cre:Cxcl12
flox/flox
 mice (A), 
Dmp1-Cre:Cxcl12
flox/flox
 mice (B), and Cxcl12
flox/flox
 control mice (A&B). Bone marrow was then 
analyzed using flow cytometry to quantify the number of different T cells, gated as T cell 
receptor (TCR)
+
 cells. Sample size, n = 4-6 mice per group in all experiments.  Data represent 
the mean ± SEM, **P < 0.01; ***P < 0.001. 
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Figure 5.2. The effects of BM cDC ablation on bone marrow stromal cells (BMSCs).  Bone 
marrow stromal cells were FACS sorted from Zbtb46
dtr
 bone marrow chimeras treated with 1 day 
of DT of PBS (n = 4 or 5 mice, respectively). Sorted cells were then used for RNA microarray 
analysis. A. Gene expression profiles from the two conditions were compared and visualized 
using t-Distributed Stochastic Neighbor Embedding (tSNE) analysis. B. The expression level of 
CXCL1 mRNA in BMSCs was quantified by probe signal. C. The expression level of CXCL2 
mRNA in BMSCs was quantified by probe signal. Data represent the mean ± SEM, **P < 0.01; 
“ns” means no significant difference. 
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Figure 5.3. The effects of BM cDC ablation on osteoblasts. A. The mRNA level of osteocalcin 
(Bglap2) in whole bone marrow of Zbtb46
dtr
 bone marrow chimeras, measured by RT-qPCR and 
was normalized to the expression level of β-actin (n = 5 mice for both groups). Zbtb46dtr bone 
marrow was transplanted into irradiated Col2.3
gfp
 mice. After 8 weeks, these chimeras were 
treated with DT or PBS for 6 days. B. The number of GFP
+
 osteoblasts was measured by flow 
cytometry (n = 4 or 5 mice, respectively). C. GFP
+
 osteoblasts were sorted by FACS and their 
mRNA level of osteocalcin was measured by RT-qPCR (n = 4 or 5 mice, respectively). Zbtb46
dtr
, 
CD169
dtr
 and CD169
dtr:
Zbtb46
dtr
 bone marrow was transplanted into irradiated wildtype recipient 
mice. After 8 weeks, these recipient mice were treated with 6 days of DT or PBS. D. The mRNA 
levels of osteocalcin in whole bone marrow of these mice were measured by RT-qPCR (n = 
6,6,5,4 mice respectively). Data represent the mean ± SEM, *P<0.05; **P < 0.01; ***P < 0.001; 
“ns” means no significant difference. Samples were compared to PBS control group unless 
otherwise indicated.  
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